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“The idea that you're basically a DNA-driven software device is not the view that 
people necessarily have of themselves. But every cell on this planet works that way in a 
biological-to-mechanical kind of fashion. No brain controlling what happens with 
DNA reading and protein synthesis in your cells. The combination of one hundred 
trillion cells gives different people different abilities to make wonderful music, to make 
science advances, to think, but every one of those cells operates in the same fashion. 
And that means we will be able to decode how the brain functions by understanding 
these same mechanisms.”  
 
J. Craig Venter 
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ABSTRACT 
Endowing cells with enhanced decision-making capacities is essential for creating 
smarter therapeutics and for dissecting phenotypes. Implementation of synthetic gene 
circuits affords a means for enhanced cellular control and genetic processing; however, 
genetic circuits for mammalian cells often require extensive fine-tuning to perform as 
intended. Here, a robust, general, and scalable system, called 'Boolean logic and 
arithmetic through DNA excision' (BLADE) is presented that is used to engineer genetic 
circuits with multiple inputs and outputs in mammalian cells with minimal optimization. 
The reliability of BLADE arises from its reliance on site-specific recombinases that 
regulate genes under the control of a single promoter that integrates circuit signals on a 
single transcriptional layer. Using BLADE, >100 circuits were tested in human 
embryonic kidney and Jurkat T cells and a quantitative metric was used to evaluate their 
performance. The circuits include a 3-input, two-output full adder; a 6-input, one-output 
Boolean logic look-up table; and circuits that incorporate CRISPR–Cas9 to regulate 
endogenous genes. Moreover, a large library of over 15 small-molecule, light and 
temperature-inducible recombinases has been established for fine-tuned control. BLADE 
enables execution of sophisticated cellular computation in mammalian cells, with 
applications in cell and tissue engineering. 
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CHAPTER ONE: The Current Progress of Mammalian Cell Genetic Tools and 
Their Usage in Understanding Disease and Scientific Discovery 
1.1 Introduction 
 Many human diseases, such as cancers, obesity, neurological disorders, and 
chronic infections, are highly complex. Substantial resources are being devoted to 
uncover the mechanisms governing disease formation, progression, and treatment. Many 
diseases are influenced by the genetics of the patients and pathogenic organisms. High-
throughput genomic and biochemical technologies, such as next generation sequencing 
[1] and protein-protein interaction network mapping [2-6] have revolutionized our ability 
to observe and discover the potential factors that may contribute to disease phenotypes. 
To validate these observations, genetic engineering has become indispensable. Disruption 
or rearrangement of DNA elements (e.g. genes, promoters) in the genome and 
overexpressing of RNAs or proteins are routinely employed to map genotypes to 
phenotypes. However, simple knockout or overexpression is often not sufficient or 
desirable. For instance, overexpression of oncogenes in the entire mouse will lead to non-
physiological development of tumors that do not mirror the progression of human tumors. 
Therefore, to better model human diseases in laboratory animals and understand the 
complex genetic network underlying many diseases, more refined spatiotemporal genetic 
modification will be required.  
Over the past two decades, synthetic biology, an interdisciplinary science 
involved in the design and construction of biological systems for enabling new and useful 
functions through genetic engineering, has witnessed remarkable advances [7-27]. The 
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efficiency of genetic modification, especially in slow growing systems such as 
mammalian cells, has improved dramatically. Multiple strategies for stably inserting 
DNA elements into the mammalian genomes, such as through retroviral transduction [28] 
or transposons [29, 30] are now available; these technologies have greatly expedited 
some of the experiment workflow. In addition, the development of targeted genome-
editing systems such as zinc-finger nuclease, TALEN, and CRISPR/Cas9 systems has 
enabled programmable modification of the genome in many organisms. Such 
enhancement of genome-editing precision is critical for strengthening the correlation 
between genotype and phenotype and engineering cell-based therapeutics. Moreover, 
novel chemical and optical genetic tools allow better spatiotemporal control of the 
genetic modification and cellular function in live animals. Spatial or tissue specificity is 
particularly important since many diseases are organ specific. Temporal precision is 
critical for developmental or event-specific diseases. 
In this chapter, I will provide an overview on some of the novel genetic 
engineering technologies. I will also illustrate how these technologies are used in 
studying disease mechanisms through a series of examples from recent literature. In 
particular, I will focus on tools developed in genome editing, chemical genetics, and 
optogenetics. While these tools have also been used in many areas of biological research, 
I will provide examples mostly from cancer and neuroscience because these two areas are 
some of the major driving forces for the development and adoption of these new 
technologies.   
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1.2 Genome-Editing Tools 
Diseases are abnormalities that alter the normal function of a living organism. 
Many diseases result from genetic alterations stemming from conception, environmental 
factors, or exposure to infectious pathogens. Therefore, for effective treatment or 
understanding of disease, robust tools for genome alterations and studies are needed. 
Various genome-editing tools will be discussed here in relationship to their usage in 
determining disease mechanisms, including site-specific recombinases, transposases, and 
nucleases. 
1.2.1 Site-Specific Recombinases 
A common strategy for studying the disease-causing or repression roles of genes 
is to follow disease formation and progression while turning the expression of genes of 
interest from a state of low or no expression to a state of higher expression, and vice 
versa. To serve this purpose effectively, simple yet powerful one-input-one-output 
genetic switches have been built using site-specific recombinase technology. 
Site-specific recombinases (SSRs) are small enzymes (~350-600 amino acids) 
derived from bacterial phage and yeast that perform site-specific DNA recombination via 
their abilities to carry out DNA-binding, DNA-cutting and DNA-ligation operations. 
Each SSR has a specific corresponding set of recombination sites, which are small DNA 
sequences typically between 30 to 200 base pairs in length. Depending on the placement 
of recombination sites around a gene of interest or a target in the genome, SSRs can 
perform site-specific deletion, inversion and translocation of DNA. SSRs are divided into 
two main classes depending on their catalytic residue, tyrosine or serine. SSRs that utilize 
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tyrosine include the tyrosine integrases, such as the λ and HK022 integrases, and the 
tyrosine recombinases, such as the Cre and Flp recombinases. SSRs that use a serine 
catalytic residue include the small serine recombinases, such as the ɣδ resolvase and Gin 
invertase, and large serine integrases, such as the ɸC31 and TP901-1 integrases [31]. 
Due to their high recombination efficiencies, speed, and simplicity, tyrosine 
recombinases have been used extensively in disease model organisms. Hundreds of 
animals have been generated for SSR-dependent gene expression or knockout by 
engineering simple one-input, one-output genetic switches [32] (Figure 1.1a). For 
conditional expression of a gene, a transcription termination “stop” sequence that is 
surrounded by recombination sites (termed “floxing” if Cre loxP sites are used) is placed 
in front of a gene of interest, thereby blocking gene expression; upon recombinase-
mediated deletion, the stop sequence is removed, leading to gene expression. For 
conditional knockout of a gene, recombination sites are placed directly surrounding the 
gene; upon recombination-mediated deletion, the gene is removed from the genome. 
Recombinase expression can be induced in several ways (Figure 1.1b). Most 
commonly, a recombinase is fused to a Type I nuclear receptor, preventing nuclear entry 
of the protein. Upon addition of a small molecule (e.g. 4-hydroxytamoxifen or RU486) 
[33, 34], the recombinase translocates into the nucleus and performs site-specific DNA 
recombination. Alternatively, a split recombinase was developed that demonstrates a 
significant increase in recombination activity upon complementation of its two halves 
using dimerization induced by a rapamycin analog and FKBP and FRB protein domains 
[35]. Chemical induction permits spatiotemporal control of SSR activity (see next section 
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for more details), which allows study of the effects of gene alterations in many stages of 
development, including those that could be otherwise lethal during embryogenesis. 
Diseases are often caused by an abnormality in a specific cell type or in the 
interplay between multiple cell types. Geneticists have been able to target gene 
expression to specific cell types by a single feature, such as a tissue-specific promoter 
that is only transcribed in a particular cell type (Figure 1.1c). Many disease model 
organisms have been genetically modified to express an SSR under tissue-specific 
promoters [36, 37] or microRNA [27, 38, 39] to restrict site-specific recombination to 
particular cell types. Furthermore, cell type specificity can be further enhanced by 
integrating multiple features using more than one tissue specific promoter and 
recombinase and using novel recombinase reporters that logically integrate those signals 
[40, 41]. 
In summary, site-specific recombinase technology has been essential for 
understanding the mechanisms underlying disease initiation, progression and regression. 
Specifically, I will highlight SSR usage in the study of cancer and neurological disorders. 
Exemplary Case 1: Pancreatic Cancer 
Pancreatic cancer remains the deadliest cancer by 5-year survival rate and the 
fourth leading cause of death by cancer in the United States [42]. Pancreatic 
adenocarcinomas (PDACs), which make up 95% of all pancreatic cancers, have been the 
focus of heavy study. Three different ductal preneoplastic lesions are potential precursors 
of PDAC; these include pancreatic intraepithelial neoplasias (PanINs), intraductal 
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papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCN). PanINs 
are classified in four grades: PanIN-1A, 1B, 2 and 3 depending on the level of dysplasia. 
Genetically engineered mouse models can successfully recapitulate the full spectrum of 
PanINs through invasive and metastatic adenocarcinomas via conditional introduction of 
Kras mutants [43]. 
The first model that faithfully reproduced all PanIN stages through to invasive 
PDAC in mice involved a knocked-in KrasG12D allele silenced by a stop cassette flanked 
with loxP sites, termed lox-stop-lox-(LSL)-KrasG12D [44]. These mice were crossed with 
animals containing the Pdx1 or Ptf1a promoter driving Cre recombinase, thereby 
expressing KrasG12D in pancreatic cells beginning from embryogenesis. The resultant 
mice displayed acinar ductal metaplasia, a benign lesion that appears prior to PanIN 
lesion formation. All stages of PanINs appeared through to eventual metastatic pancreatic 
cancer. Further developments were made in this mouse model by incorporating tamoxifen 
or doxycycline inducible Cre vectors. Models found that inducing KrasG12V mutant 
expression in adult mice only developed into pancreatic cancer when the animal 
underwent pancreatitis. Furthermore, additional mutations in tumor suppressor loci, such 
as TP53, SMAD4, INK4A, and LKB1 accelerated progression of PanIN lesions to 
generation of invasive PDAC. 
Although these models have made much progress in our understanding of 
pancreatic cancer development, they are limited in the extent of genetic perturbation they 
allow. An enhanced PDAC model was recently generated that overcomes the limitations 
of single step KrasG12D or KrasG12V gene activation, by utilizing dual-step gene activation 
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via usage of both Cre and Flp recombinases [45] (Figure 1.2). This work used a series of 
sequential recombination events via Flp recombinase control of both KrasG12D and Cre-
ERT2 expression. The Trp53 tumor suppressor gene was floxed and after tamoxifen 
administration there was a rapid formation of multifocal PDAC; untreated mice only 
showed PanIN lesions. To test whether the system could validate therapeutic targets, a 
floxed Pdpk1 gene was used, an important downstream effector of phosphoinositide 3-
kinase and KrasG12D mediated PDAC progression. It was found that Cre-mediated 
ablation of Pdpk1 almost completely blocked tumor progression in PanIN-bearing mice. 
Moreover, the group modeled disease treatment by using a lox-stop-lox diphtheria toxin 
A (DTA) cassette. Tamoxifen treated mice exhibited rapid regression of tumor volume, 
whereas untreated mice proceeded with tumor progression. 
Exemplary Case 2: Lung cancer 
Lung cancer remains the leading cause of cancer-associated deaths in the United 
States [42]. Many genetically engineered mouse models of lung adenocarcinoma have 
focused on Kras mutations, particularly those on codon 12 that generate formation of 
lung tumors [46, 47]. A seminal work utilized conditional KrasG12D activation to study 
timing and multiplicity of tumor initiation [48]. A genetically engineered mouse was 
generated with a KrasLSL-G12D/+ genotype. Deletion of the lox-stop-lox cassette was 
achieved by introduction of Cre recombinase through adenovirus intranasal delivery. 
Histological analysis of the lungs of these animals revealed formation of three types of 
lesions: atypical adenomatous hyperplasia (AAH), epithelial hyperplasia (EH) of the 
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bronchioles, and adenomas. The AAH exhibited in these mice resembled human AAH, a 
dysplastic lesion proposed to be a precursor of lung adenocarcinoma. By infecting 
different dosages of the virus, the group observed an increasing number of lesions and 
demonstrated that they could control the tumor multiplicity. No lesions were observed 
with wild-type mice infected with any of the viral dosages. 
One of the prominent questions was which cell type initiated lung 
adenocarcinomas. Within the lesions, there were double-positive surfactant apoprotein-C 
(SP-C) and Clara cell antigen (CCA) cells, characteristics of alveolar type II or Clara 
cells, respectfully. The results suggest that there is epithelial plasticity, such that 
oncogene activation induces hyperproliferation of Clara cells, which then 
transdifferentiate as they move into the alveolar compartment, as the double-positive cells 
were situated at the end of a row of Clara cells and extend into the alveolar compartment. 
Additionally, the CCA expression was lower in double-positive cells than the nearby 
Clara cells. 
Exemplary Case 3: Huntington’s Disease 
Huntington’s disease (HD) is a neurodegenerative disorder that arises by a CAG 
repeat expansion encoding a polyglutamine (polyQ) repeat in the N terminus of the 
huntington gene (htt) [49]. There currently is no effective treatment or cure to HD and 
patients will eventually succumb to psychiatric and cognitive deficits and death in 
adulthood. Unfortunately, the molecular and cellular mechanisms behind HD progression 
remain largely unknown. 
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One group investigated whether HD-mediated neuronal degeneration is only 
caused by cell-autonomous toxicities of the polyQ mutated huntington gene (mhtt) or if it 
requires pathological interactions between cells [50]. A Cre/loxP conditional mouse 
model of HD was established to test whether the first model (cell-autonomy) or the 
second model (cell-cell interaction) was at play. The mouse model (RosaHD) contained a 
lox-stop-lox-mhtt-exon1 cassette driven by the Rosa26 locus promoter. Note this is not 
the full mhtt protein, rather just the first exon. It is hypothesized that the expanded polyQ 
repeat of the mhtt protein leads to proteolytical cleavage of the protein and release of N-
terminal fragments. It has been noted that accumulation of small aggregated mhtt N-
terminal fragments (including mhtt-exon1) in both HD patients and transgenic mice was 
observed prior to onset of motor deficits and neuronal degeneration and are more toxic 
than the full mhtt protein. RosaHD mice were either crossed with a Nestin-Cre mouse, 
which activates loxP recombination in all neurons and glia in the brain, or an Emx1-Cre 
mouse that permits Cre-mediated recombination in all cortical pyramidal neurons and 
glia, but not in cortical interneurons or striatal neurons. It was found that restricting mhtt 
expression to cortical pyramidal neurons via Emx1-Cre was sufficient to elicit mhtt 
nuclear accumulation and aggregation; however, it was insufficient to produce other 
cortical neuropathology or motor deficits. Moreover, cortical interneuron dysfunction by 
expression of mhtt outside cortical pyramidal neurons is critical for HD pathogenesis; 
therefore, cell-cell interactions were critical for cortical pathogenesis in the RosaHD 
conditional mouse models. 
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1.2.2 Site-Specific Transposases 
Site-specific transposases are enzymes that bind to ends of particular mobile DNA 
sequences (transposons) and catalyze the integration of transposons into different sections 
of the genome. Due to their efficiency and large DNA payload, they have been widely 
used for non-viral integration of foreign DNA into chromosomes of vertebrate animals, 
with the Sleeping Beauty (SB) and piggyBac (PB) transposon systems being the most 
popular. The SB transposon system was “resurrected” from extinct transposase sequences 
belonging to the Tc1/mariner class of fish transposons, whereas, the PB transposon 
system was isolated from the cabbage looped moth Trichoplusia ni genome [51]. Donor 
DNA flanked by transposase recognition sequences is inserted into TA or TTAA sites in 
the genome by SB or PB-mediated transposition, respectfully. In contrast to the SB 
system, piggyBac has been shown to permit delivery of near limitless lengths (> 100kb) 
of DNA into the genome [52] and can be removed without creating scars in the genome. 
Additionally, reports have shown the PB transposase system to integrate DNA into 
human cells more efficiently than the SB system and each system prefers different target 
locations in the genome [53, 54]. Both systems are very useful for inducing genome-wide 
mutagenesis and introduction of exogenous proteins and RNAs. 
Exemplary Case 1: Cancer Hallmarks 
Due to their ability to integrate DNA into the genome, the SB and PB 
transposases have been utilized for cancer gene discovery. The Bradley group and 
colleagues developed constitutively expressing SB and PB transposase knockin mice, 
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RosaPB and RosaSB, respectfully, for genome-wide mutagenesis and tumor suppressor 
and oncogene identification [55]. A host of other mouse lines were generated containing 
dual SB/PB transposons with splice-acceptor and transcription termination sequences (for 
gene inactivation) followed by promoter and splice-donor sequences (for gene 
activation). Promoter and enhancer sequences were altered to provide a range of gene 
activation. Transposons were located on 14 different chromosomes and 2 to 150 
transposon copies. Intercrossing of RosaPB and high-copy transposon lines did not 
produce live-born double-positive progeny, though double-transgenic embryos were 
identified, indicating transposition-induced embryonic lethality. Crossing of RosaPB and 
low-copy transposon lines produced double-positive transgenic offspring at or near 
Mendelian frequencies. 393 animals were monitored from multiple cohorts for PB-
mediated mutagenesis-induced cancer development. After two months of age, only 
double-transgenic (transposase/transposon) mice developed cancers. Tumor type varied 
depending on promoter sequence with one producing primarily aggressive leukemias and 
lymphomas, and another with almost exclusively solid tumors. This was attributed to 
variable promoter tissue specificity. More than 50,000 transposon integration sites were 
cloned and a total of 5590 non-redundant insertions were identified. A statistical 
framework was used to determine candidate cancer genes. The test identified 72 unique 
common integration sites (CISs) at 67 independent loci. It was found that 42% of the 
CISs were previously not determined, underscoring the usage of PB transposase for 
tumor suppressor and oncogene screens. Integration patterns differed between oncogene 
or tumor suppressor CISs. Oncogenic insertions tended to be in specific regions where 
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transposons could yield gene activation (i.e. prior to translation start site or within an 
intron prior to an exon). Tumor suppressor gene insertions were randomly distributed 
among genes, in either sense or anti-sense orientations, indicating gene disruption as the 
disease-causing mechanism. Some novel candidate cancer genes from the screen include 
PU.1-related transcription factor Spic, the histone deacetylase Hdac7, the Wnt pathway 
component Bcl9 and cell cycle regulatory phosphatase Cdc14. The method was enhanced 
in a follow up project, which achieved spatiotemporal PB-mediated mutagenesis through 
use of a tamoxifen-inducible PB targeted to specific cell types via Cre/loxP site-specific, 
recombinase-based technology [56]. 
1.2.3 Site-Specific Nucleases 
The capacity to target a specific locus in a living organism’s genome for genetic 
perturbation is a powerful avenue for therapeutic treatment of genetic diseases and 
identification of disease mechanisms. Disease-causing DNA sequences could be replaced 
with proper wild type sequences. Engineered mutations in a gene’s sequence could help 
inform us of its structure and function, and targeted gene overexpression or knockdown 
could elucidate the dynamics of gene regulatory networks. 
Precise genome-editing ability is critical to achieve this goal, and there are 
multiple genome-editing systems available in eukaryotic cells. Zinc-finger nucleases are 
one of the earliest targeted genome-editing tools. They are made through a fusion of 
DNA-binding zinc finger domains fused to a DNA-cleavage domain, such as FokI. 
Multiple zinc finger DNA-binding proteins, which each bind up to three base pairs, can 
be assembled in an array to target DNA sequences up to 18 base pairs, allowing a single 
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locus to be targeted in the human genome. If using a DNA-cleaving domain like FokI, 
two zinc-finger nuclease arrays are necessary as FokI needs to be dimerized to function. 
This provides better specificity and lowers off-target nuclease activity as the target DNA 
sequence length has doubled. ZFNs can be difficult to create as the DNA sequence 
specificity of zinc finger proteins is not easily programmed. A newer technology termed 
Transcription Activator-Like Effector Nucleases (TALEN) affords significant ease in 
programmability as each domain of a TALEN can bind specifically to an adenine, 
cytosine, thymine, or guanine. Nevertheless, the cloning and delivery of TALEN 
constructs can be difficult as they contain DNA repeats and are often too large to package 
into viruses [57]. 
A recent advancement in the genome-editing field has been the use of the Cas9 
protein, an RNA-guided endonuclease in the microbial adaptive immune system, 
CRISPR (clustered regularly interspaced short palindromic repeats) [58] (Figure 1.3). 
The CRISPR/Cas9 system has been adapted for use in gene editing and regulation in both 
prokaryotes and eukaryotes, including human cells. To target a locus for genetic 
modification, a single guide RNA (sgRNA) can be supplied that contains a 20 base 
sequence complementary to the locus of interest and that is adjacent to a short 
protospacer adjacent motif (PAM) sequence. The sgRNA binds to the Cas9 protein, 
which scans the genome for a complementary sequence to the target in the genome. Once 
the target sequence has been found, Cas9 enzymatically generates a double-stranded 
break within the target sequence. Nonhomologous end-joining can lead to insertions or 
deletions (indels) of varying lengths at the site of double-stranded break, which can be 
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utilized for gene-specific mutation. Furthermore, donor DNA can be integrated through 
homology directed repair for gain-of-function genome modifications. Finally, synthetic 
transcription factors for genome-wide gene expression alteration have been engineered by 
using catalytically inactive Cas9 proteins (dCas9) that have been fused to transcription 
activation or repression domains [59-62]. 
Nonetheless, all three of these genome-editing enzymes display a degree of off-
target modifications with Cas9 being less stringent on nucleotides near the 5’ terminus of 
the sgRNA [63-66]. A nickase Cas9 (nCas9) that creates single stranded nicks can be 
used for more specific integration by use of two sgRNAs for cleavage of a DNA 
molecule [67]. Additionally, large mutagenesis efforts recently found Cas9 mutants, 
eSpCas9(1.1) and SpCas9-HF1, with considerably less off-target modifications [68, 69].  
Exemplary Case 1: Liver Cancer 
Tyler Jacks and colleagues demonstrated that the CRISPR/Cas9 system could be 
used to generate liver cancer disease mouse models. They used hydrodynamic tail vein 
injection to deliver CRISPR plasmid DNA expressing Cas9 and sgRNAs to the liver that 
target the Pten and p53 tumor suppressor genes for generation of DNA insertions and 
deletions (indels) [70]. Deep sequencing revealed a small percentage of indels in either 
the Pten or p53 loci at the sgRNA targeted locations. The group did not observe liver 
tumor formation in mice with sgRNAs only targeting Pten or p53 after three months, 
however, if both Pten and p53 sgRNAs were delivered simultaneously, tumors developed 
in the liver with bile duct differentiation features. Furthermore, the group demonstrated 
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the CRISPR/Cas9 system could be used for gain-of-function mutations by co-delivering 
Ctnnb1-targeting sgRNAs to the Ctnnb1 locus along with a 200-nucleotide single-
stranded DNA molecule containing four point mutations that mutate serine or threonine 
residues to alanine. These mutations were previously shown to permit nuclear 
localization of β-catenin. The research group was able to reaffirm this phenotype by 
observing a small fraction of hepatocytes that exhibited β-catenin nuclear localization in 
mice where both the sgRNAs and ssDNA were co-delivered as opposed to mice that only 
received the sgRNAs. 
Exemplary Case 2: Lung Cancer 
A group led by Tyler Jacks created a novel vector (pSECC) to simultaneously 
introduce Cas9, sgRNA, and Cre recombinase lentivirally to genetically engineered 
mouse models of lung adenocarcinoma with either KrasLSL-G12D/+ or KrasLSL-G12D/+; 
p53flox/flox genotypes, where administration of Cre induces lung tumor formation [70]. In 
order to investigate the roles of three tumor suppressor genes in relation to tumor 
development of KrasLSL-G12D/+ and KrasLSL-G12D/+; p53flox/flox mice, sgRNAs that target 
either the Nkx2-1, Pten, and Apc tumor suppressor genes were introduced into the 
pSECC vector system. Animals that were infected with pSECC viruses targeting Nkx2-1 
were found to have mucinous adenocarcinomas and glandular rearrangements in 
agreement with previous data using Nkx2-1flox/flox mice. A complete loss of the Pten 
protein in 74% of tumors with accompanying increased pAkt (S473) was found in mice 
infected with pSECC viruses with Pten-targeting sgRNA. Furthermore, the group 
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investigated a tumor suppressor gene, adenomatous polyposis coli (Apc), which was not 
yet characterized with respect to its role in lung adenocarcinoma. Formed tumors were 
highly dedifferentiated, invasive, had a significant stromal component and exhibited 
identical histopathology as tumors formed from mice with KrasLSL-G12D/+; Apcflox/flox. 
Overall, their analyses showed distinct histological and pathway-specific differences 
upon CRISPR/Cas9-guided mutation of Nkx2-1, Pten, and Apc. With respect to 
tumorigenesis, Pten mutations yielded statistically significant increases in overall tumor 
burden in both KrasLSL-G12D/+ and KrasLSL-G12D/+; p53flox/flox mice; however, Nkx2-1 
guided deletion only had a significant tumorigenic effect in KrasLSL-G12D/+; p53flox/flox 
mice and Apc deletions were significant only in KrasLSL-G12D/+ mice. 
A new work generates an oncogene present in a small subset of human non-small 
cell lung cancers by utilizing CRISPR/Cas9-guided chromosomal rearrangements [71]. 
The group generated the echinoderm microtubule-associated protein like 4 and anaplastic 
lymphoma kinase (EML4-ALK) oncogene fusion by inducing double-stranded breaks in 
the Alk and Eml4 genes and observing a small fraction that inverted the regions between 
the two loci, creating the Eml4-Alk fusion protein, which was confirmed by sequencing 
and direct visualization by interphase FISH. Similarly, the Npm1-Alk rearrangement a 
chromosomal event often observed in anaplastic large cell lymphomas, was modeled. To 
induce the Eml4-Alk translocation in vivo, mice were intratracheally infected with an 
adenovirus containing Cas9 and the Alk and Eml4 targeting sgRNAs. After a month post-
infection, the lungs of the mice presented multiple small lesions that appeared to be EH 
of the bronchioles, AAH, or early well-differentiated adenocarcinomas. At 12 – 14 weeks 
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post-infection, the lungs contained multiple large lesions characterized as 
adenocarcinomas. The tumors were further examined for responsiveness to the drug 
crizotinib, a dual ALK/MET inhibitor used to treat ALK+ non-small cell lung cancers. 
After two weeks of treatment, 6/7 animals treated with the drug displayed complete 
tumor regression and 1/7 showed partial regression as indicated by µCT scans and 
confirmation at necropsy; all animals that were not treated with the drug showed 
continued diseased progression. 
Exemplary Case 3: Neurological Disorders 
One study has used the CRISPR/Cas9 system to study the role of multiple genes in the 
formation of Rett syndrome [72]. The authors wanted to validate if the CRISPR/Cas9 
system could recapitulate results obtained in earlier works, which demonstrated that 
deficiency of the MeCP2 gene can lead to multiple symptoms that occur in a person with 
Rett syndrome, including significant morphological and electrophysiological effects. 
Single guide RNAs were designed to target exon 3 of the mouse Mecp2 gene. Co-
infection of an adeno-associated virus expressing SpCas9 under a short Mecp2 promoter 
and a virus expressing sgMecp2 and GFP under a neuron-specific human Synapsin I 
promoter into mouse primary cortical neurons led to >70% of transduced GFP+ cells to 
be MeCP2 negative as confirmed by immunocytochemistry and western blot analysis. 
Targeted neurons were phenotypically similar to those seen from MeCP2 loss-of-
function, as there were appearances of dendritic tree abnormalities and spine 
morphogenesis defects. The viruses were injected into hippocampal dentate gyrus of 
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adult male mice. Using next generation sequencing, it was found that ~68% of the cells 
contained indel mutations in the targeted Mecp2 locus. Contextual fear-conditioning 
behavior tests revealed that MeCP2 inactivation in the dentate gyrus mediated by 
CRISPR/Cas9, impaired contextual learning but left other cognitive abilities intact. 
Furthermore, the mRNAs from GFP+ cells were sequenced and 34 genes were found to 
be differentially expressed between neurons receiving sgMecp2 and control sgRNA. 
1.3 Chemical and Optical Genetics 
Genome-editing tools have revolutionized how I interrogate biological systems. 
However, on their own, genome-editing tools do not have the necessary spatiotemporal 
precision needed to study some of diseases. Chemical and optical genetics provide 
complementary tools to control cellular functions with chemical (usually small 
molecules) or light for precise, fast, and reversible spatiotemporal control of protein 
activity. 
Chemical genetics involves the use and study of small molecules for perturbation 
of biological processes. Typically, small molecules that can directly alter the activity of 
endogenous biomolecules such as proteins would be identified [73]. I will focus on a 
particular variation of this approach where chemically controllable protein domains are 
fused to a protein of interest. Administration of the chemical regulates either the 
dimerization or stability of the protein domain and hence the protein of interest that is 
fused to them.  
Optical genetics involves the use of light to control cellular function. This 
approach typically is achieved through the expression of proteins (e.g. microbial opsins 
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and light-oxygen-voltage domains) where their activity is controllable with light [74]. 
The use of light is advantageous because its administration (and removal) can be 
extremely rapid (~ms), and highly localized, which cannot be accomplished to this degree 
with chemical genetics. However, special equipment is needed to implement this 
approach and tissue penetration of the light in live animals remains a major obstacle. 
Nonetheless, optogenetics has found wide usage in neuroscience because of the need for 
rapid and localized control of neuron activity.  
In addition to regulating cellular function, chemical and optical genetics 
approaches have also led to the development of cell state reporters [75, 76]. In particular, 
one of the most exciting developments in neuroscience is the development of genetically 
encoded calcium sensors. Intracellular calcium influx is one of the hallmarks of neuron 
activation. These sensors produce enhanced fluorescence when intracellular calcium 
levels increase and embody some of the key features of chemical and optical genetics. In 
this section, I will discuss how these tools, often time in conjunction with other 
biochemical and genome-editing technologies, are used to investigate disease 
mechanisms. 
1.3.1 Chemical-Inducible Dimerization 
The first discovery of a naturally occurring chemical inducible dimerization 
system involved the finding that an immunosuppressant drug FK506 was reported to 
inhibit T cell reporter signaling through simultaneous binding to the FK506-binding 
protein (FKBP12) and calcineurin [77, 78]. A chemical dimer of FK506, termed FK1012, 
was synthesized and shown to dimerize FKBP12 molecules. As this system was limited 
		
20 
to homodimerization, a heterodimerization system that was derived from the rapamycin 
(mTOR) signaling pathway was developed (Figure 1.4). In this system, FKBP12 forms a 
heterodimer with the FKBP-rapamycin-binding (FRB) domain of the mTOR protein upon 
simultaneous rapamycin binding. Nevertheless, as this system competes with endogenous 
proteins for rapamycin binding, unintended interactions  can occur and inhibition of 
mTOR can lead to cell-cycle arrest. To remove reliance on the natural rapamycin 
molecule, a FKBP12F36V protein can be homodimerized by a rapamycin analog AP20187; 
furthermore, FKBP12 and FRBT2098L can be heterodimerized by AP21967. However, the 
affinity of rapamycin to its protein binding is extraordinarily high, such that dimerization 
is essentially irreversible, unless it is outcompeted through exogenous supply of FK506 
[78]. An alternative and reversible chemical dimerization system was discovered that 
uses plant phytohormone abscisic acid that can be washed out [79]. Finally, a system 
based on plant hormone gibberellin was used in conjunction with the rapamycin system 
to permit multiplexed and logical control of cellular processes [80, 81]. 
Exemplary Case 1: Leukemia 
The mixed lineage leukemia (MLL) gene is often mutated in infant and adult 
acute leukemias. As a result of chromosomal rearrangement, MLL has been found to fuse 
to up to fifty diverse partner proteins of nuclear or cytoplasmic origin; regardless, the 
fusion proteins are always in-frame chimeras that preferably occupy the nucleus rather 
than the cytoplasm. To determine a common oncogenic mechanism despite the apparent 
fusion protein diversity, a variety of molecular techniques was used to study two MLL 
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chimeras, MLL-AF1p and MLL-GAS7 [82]. Mutations were directed to each of the 
partner proteins and revealed the requirement of coiled coil motifs towards MLL 
oncogenic activation. It was hypothesized that addition of these coiled coil motifs from 
the partner proteins induced homodimerization via coiled coil-mediated binding. To 
investigate if dimerization was sufficient for oncogenic activation, MLL was fused to 
either a FKBP or FRB heterodimerization domain. Expressing just MLL-FKBP or MLL-
FRB with or without AP21967 did not lead to colony formation; however, co-expression 
of the two fusion proteins in addition to AP21967 molecule, induced oncogenesis. 
Further investigation suggested that the MLL-GAS7 and MLL-AF1p chimeric proteins 
created a transcriptional activator complex that might recruit unknown cofactors. 
Exemplary Case 2: Obesity 
A ‘fatless’ mouse model, dubbed FAT-ATTAC (fat apoptosis through targeted 
activation of caspase 8), was developed where adipocytes can be targeted for destruction 
via small-molecule induction [83]. Two catalytic domains of human caspase 8 were fused 
to F36V FKBP mutants that can be tethered together through homodimerization by 
FK1012 analog, AP20187. An adipocyte-specific promoter Fabp4 was used for 
expression of the fusion protein in mice. Within one to two weeks of chemical dimerizer 
treatment, white and brown fat could be ablated. Short-term treatment disrupted local 
adipose tissue structure and macrophage infiltration; long-term treatment resulted in 
apoptosis of a majority of adipocytes with dropped levels of adipokines (adiponectin and 
resistin), and glucose intolerance with no difference in serum insulin, glucose, 
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triglycerides, or free fatty acids. Circulation of leptin levels dropped in fatless mice with a 
corresponding increase in food intake. Removal of the dimerization agent reversed the 
phenotype, yet adipokine levels rebounded to only ~50% of baseline levels and glucose 
intolerance persisted for six weeks. To assess the role of leptin in regards to the metabolic 
phenotype and changes in FAT-ATTAC mice, the FAT-ATTAC system was introduced 
into mice with a homozygous point mutation in the leptin gene (ob/ob) that induces 
excessive eating and obesity. During drug treatment, massive weight loss, increased 
metabolic rate and increased liver steatosis of FAT-ATTAC ob/ob animals were observed 
over ob/ob mice. MCP-1 (monocyte chemotactic protein 1) levels increased four-fold, 
which suggests that cells other than adipocytes can contribute significant levels of MCP-1 
production. Furthermore, fatless FAT-ATTAC ob/ob mice showed decreased glucose-
stimulated insulin secretion with no change in pancreatic islet area or morphology despite 
showing the expected increase in insulin levels in response to glucose challenge prior to 
fat loss. These data indicate that an adipocyte-specific factor could be necessary for 
maximal glucose-stimulated insulin secretion that is absent in fatless mice. 
1.3.2 Chemical-Inducible Protein Stability 
An ideal protein control system entails fast, precise, and reversible modulation of 
protein expression level without perturbation of native protein interaction and 
transcriptional regulation. Cre/loxP-based genome-editing technology has been a 
powerful tool for genetic control, but lacks reversibility. Small-molecule inducible 
protein stabilization systems carry the benefits of recombinase-based approaches (i.e. 
minimal interference of genomic context and spatiotemporal control), but permit 
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reversible control. The FKBP/rapamycin system has been engineered as a control system 
for protein stability. FKBP12 mutants fused to YFP were discovered to have instability in 
the absence of a small-molecule, Shield1; instability was found to be mediated, at least in 
part, by proteasomal degradation mechanisms [84]. Upon administration of Shield1, a 
small molecule, the protein fusion recovers complete stability and activity. A particular 
FKBP degradation domain, FKBPL106P, termed DDFKBP, performed the best with maximal 
degradation and recovery. Other domains that demonstrate small-molecule inducible 
protein stability, include DDDHFR [85] and DDERLBD [86], which are stabilized upon 
addition of trimethoprim or 4-hydroxytamoxifen, respectfully. Chemical-inducible 
protein stability control is perhaps an easier system to design and implement to control 
protein activity than chemical-inducible heterodimerization approaches, which require 
finding an effective location to split a protein and deliver both halves. 
Exemplary Case 1: Cancer Hallmarks 
A group utilized the Shield1-inducible protein regulation to assess the roles of 
various cancer genes [87]. To make endogenous genes controllable by Shield1, 
PuromycinR-2A-DDFKBP sequences were knocked in upstream of each gene via use of 
TALENs or the Cas9 RNA-guided endonuclease. They termed this system Degron-KI as 
it used knock-in technology for introducing degradation domains in frame with 
endogenous genes. The first cancer gene to be studied was the known tumor suppressor 
TP53 gene in HTC116 cells. The DNA damage-response pathway activated robustly 
through examination of p21 expression after Shield1 was administered to cells with DD-
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p53 along with DNA-damaging agent doxorubicin. However, if Shield1 was removed, 
and thus p53 was degraded, the response to DNA damage was strongly suppressed. 
Shield1 had no effect on wild type cells without the fusion of the Shield1-sensitive DD to 
p53. Furthermore, DD-p53 with Shield1 responded to MDM2 inhibitor Nutlin-3 similarly 
to cells with normal p53. An oncogene was investigated next, the EZH2 gene, which 
codes for a histone-lysine N-methyltransferase enzyme that inhibits genes responsible for 
suppressing the development of tumors. A DD tag was introduced into cells that 
contained a mutation of EZH2 that was sensitive to EZH2 inhibitors. Removal of Shield1 
from DD-EZH2 cells resulted in inhibition of H3K27 trimethylation, a major histone 
substrate of EZH2. Furthermore, withdrawal of the drug also impaired proliferation of 
DD-EZH2 in a dose-dependent manner, mimicking selective dependence on 
pharmacologic EZH2 inhibitors. Finally, the usage of the Degron-KI system was used to 
investigate and characterize a less understood oncogene, SF3B1, that is part of the 
spliceosome. Due to the role of SF3B1 in splicing, a function critical to cellular 
processes, questions were raised about the safety of SF3B1 inhibitors with respect to 
normal, non-cancerous cells. Withdrawal of Shield1 from heterozygous SF3B1DD/+ cells 
showed no impact in growth of normal cells, whereas, homozygous SF3B1DD/DD cells had 
dramatically impaired growth. The SF3B1 gene was further investigated in cancer cell 
lines that expressed mutated SF3B1 variants. The wildtype SF3B1 sequence was found to 
be critical for cell survival, however, SF3B1K666N was not in the endometrial cell line 
ESS-1. Moreover, the use of the Degron-KI system demonstrated that SF3B1R625G in the 
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uveal melanoma cell line Mel202 is causally linked to alternative splicing of two genes: 
UQCC and CRNDE. 
Exemplary Case 2: Neurodegeneration 
Wallerian degeneration results from damage to nerve fibers such that part of the 
axon is separated from the neuron cell body. Interestingly, a mutation called Wallerian 
degeneration slow (WldS) significantly delays axonal degeneration. The mutation 
encompasses an 85-kb tandem triplication in the mouse chromosome 4 [88], resulting in 
the fusion of two genes: nicotinamide mononucleotide adenylyl transferase 1 (Nmnat1) 
and ubiquitination factor e4B (Ube4B) [89]. Nmnat1 is involved in the biosynthesis of 
NAD+ and is hypothesized to contribute to axonal protection through increased nuclear 
NAD+ levels and resulting gene regulatory network changes. Although WldS is primarily 
found in the nucleus due to the nuclear localization signal of Nmnat1, small amounts 
have been found in the axoplasm, which suggests that the Ube4B portion partly redirects 
some WldS proteins away from the nucleus and towards the axon. To investigate these 
hypotheses further, the WldS protein was made chemically inducible through Shield1-
mediated protein stabilization of DDFKBP-WldS fusion proteins [90]. Shield1 was 
administered or was absent before and/or after laceration of axons (axotomy). It was 
found that Shield1 was required post-axotomy for neurodegeneration protection. 
Furthermore, a critical window for rescue of axonal degeneration was determined by 
adding Shield1 at different time points. Only time points of four hours and less yielded 
protective benefits, whereas, Shield1 administration after four hours did not. Although 
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there was leaky expression of WldS in the absence of Shield1, this was not enough for 
axonal protection. Therefore, these results suggested that increasing expression of axonal 
WldS was sufficient to restore axonal connectivity after axotomy, though only for a 
specific window of time. Furthermore, the group confirmed others’ observations that 
extracellular NAD+ to WT neurons after axotomy induced similar delayed 
neurodegeneration protection as the WldS mutation and further established the effect was 
limited to the same four-hour window as found using DDFKBP-WldS. 
1.3.3 Microbial Opsins 
Early work described light-driven ion pumps (opsins) in archaeons, which 
pumped protons out of cells in response to green light [91]. Further discovery found a 
blue-light responsive opsin, channelrhodopsin (ChR), that functioned in mammalian cells 
[92, 93]. The protein was soon reported to be capable of rapidly depolarizing neurons 
with high spatiotemporal precision through permitting passage of positively charged ions 
into the cytoplasm [94, 95]. What made this discovery revolutionary and door-opening 
was that the protein could be genetically targeted to different cell types and conditional 
parameters. Now, the roles of particular neurons in the context of functioning brains 
could be teased out relatively easy through light delivery. Other opsins were found to 
silence neuronal activity through cellular hyperpolarization via entry of chloride ions 
(halorhodopsin) or exit of hydrogen ions (archaerhodopsin) (Figure 1.5). Moreover, 
these opsins were responsive to yellow light and therefore allowed for multi-color 
neuronal activation or inhibition within the same organism. Green light inducible G-
protein-coupled receptors were later developed to control signaling pathways within 
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cells, including cyclic AMP and IP3 signaling. A large library of optogenetic tools has 
been developed through large mutagenesis efforts, which exhibit different excitation and 
emission spectra along with a wide range of response times, providing more flexibility in 
experimental design [96, 97]. Together, these novel genetic tools have spurned an 
incredible amount of literature studying detailed mechanisms of neuronal function and 
disease progression, of only a few I will highlight in detail.  
Exemplary Case 1: Obsessive-Compulsive Disorder 
Obsessive-compulsive disorder (OCD) is characterized by repetitive mental or 
behavioral compulsions and is a common cause of illness-related disability. The exact 
pathophysiology of OCD is unknown, though there is evidence that implicates 
dysregulation within cortico-striato-thalamo-cortical circuits (CSTC). A study tried to 
determine if there was a causal relationship between CSTC and OCD by optogenetically 
targeting neurons in the orbitofrontal cortex (OFC) and ventromedial striatum (VMS), 
brain regions where previous imaging studies suggested that hyperactivity in these areas 
is associated with OCD pathology [98]. Optogenetic stimulation was targeting to 
glutamatergic neurons in the OFC via infection of an adeno-associated virus with a 
floxed ChR2-YFP gene to EMX-Cre transgenic mice. Just five minutes of light 
stimulation over the course of five consecutive days showed a progressive increase in 
grooming activity, a mouse behavior related to OCD, in activated ChR2+ mice over non-
activated ChR2+ mice. Finally, the group tested whether a medication regimen could 
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reverse the repetitive behaviors of OCD. They found that after administrating fluoxetine 
for two weeks, there was significant diminishment of grooming behavior. 
Exemplary Case 2: Anxiety-Related Diseases 
Neurological circuitry mechanisms have been explored for anxiety-related 
disorders. Utilizing optogenetic tools, one work examined the role of activation and 
inhibition of basolateral amygdala (BLA) terminals in the central nucleus of the 
amygdala (CeA) in anxiety-related behaviors [99]. BLA glutamatergic projection neurons 
were targeted for light-induced activation via infection of an adeno-associated virus 
serotype 5 containing a CaMKIIα promoter driving ChR2-YFP expression. Illumination 
parameters were tuned to selectively control BLA terminals without nonspecific control 
of other BLA neurons. Mice were subjected to two anxiety tests: the elevated-plus maze 
(EPM) and the open-field test (OFT). As mice exhibit anxiety-related behaviors in open 
spaces, more time spent in open areas would indicate reduced anxiety. Both tests revealed 
that light stimulation in ChR2-YFP+ mice yielded lower anxiety levels versus mice with 
only a YFP+ transgene. Moreover, the group investigated if light-induced neuronal 
inhibition via halorhodopsin (eNpHR3.0) could reverse existing anxiety-reducing 
processes. Viruses with the eNpHR3.0 gene under the CaMKIIα promoter were similarly 
directed to BLA terminals in the CeA. Mice were exposed to the EPM and OFT tests 
with light-stimulation. Animals with light-stimulation of eNpHR3.0 in the CeA region 
demonstrated reduced open area activity versus illumination of YFP in the CeA or all 
glutamatergic BLA somata. 
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Exemplary Case 3: Glioma 
Glioma is a devastating cancer of the neuron-supporting cells, glial cells, in the 
brain. Optogenetics has been used to understand the mechanism of glioma progression in 
vivo. A particular study investigated whether activated neurons in glioma mouse models 
could promote development of a high-grade glioma xenografted from humans into living 
mice [100]. Prior work demonstrated that neuronal activation had a strong mitogenic 
effect on normal neuronal and oligodendroglial precursor cells; thus, questions were 
raised if this effect could also apply to oncogenic glial cells. To investigate, the authors 
established a xenograft glioma mouse model for spatiotemporal activation of neurons 
could be achieved through optogenetic stimulation. Creation of the mouse line involved 
crossing a mouse expressing ChR2 (Thy1-ChR2) in deep cortical projection neurons with 
an immunodeficient mouse (NOD-SCID-IL2R γ-chain-deficient, NSG). Next, cells from 
the frontal cortex of a 15-year old male patient with pediatric glioblastoma were 
xenografted into the premotor cortex of juvenile Thy1-ChR2; NSG mice. Optogenetic 
experiments began after two months post-engraftment. Single or repetitive light 
stimulation had no effect in control mice without ChR2 (NSG); however, there was a 
significant increase in the number of proliferating tumor cells, indicating that 
optogenetically activated cells stimulated glioma proliferation. To determine if and what  
secreted molecular factor or factors were responsible for generating this mitogenic effect, 
cortical slices from Thy1-ChR2; NSG and WT mice optogenetically stimulated similarly 
to the in vivo experiments and conditioned medium (CM) was collected. High-grade 
glioma cells derived from patients were then exposed to the CM; consequently, the cells 
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that were introduced to CM from optogenetically stimulated Thy1-ChR2; NSG slices, 
exhibited an increased proliferative index with respect to all control conditions. Further 
experiments determined that a synaptic protein neuroligin-3 was the leading secreted 
protein candidate responsible for the mitogenic effects that activated neurons can impart 
on glioma cells. 
Exemplary Case 4: Parkinson’s Disease 
Parkinson’s disease is characterized by diminished dopamine production resulting 
from neuronal cell death in the substantia nigra of the midbrain [101]. Recently, 
engraftment of stem-cell derived neuronal cells into animal models has shown behavioral 
recovery [102, 103]. Through an optogenetic approach, a study further investigated the 
mechanisms driving the recovery of such engrafted cells [104]. The yellow light 
inducible neuronal silencing halorhodopsin eNpHR3.0 fused to YFP was transduced into 
undifferentiated human embryonic stem cells; an unfused YFP gene was used as a 
control. The genetically modified cells were converted into mesencephalic dopaminergic 
(mesDA) neurons using an established approach [102]. After confirming optogenetically-
regulated neuron-silencing effects eNpHR3.0-YFP through monitor of calcium release, 
dopamine secretion was verified through reverse phase high-performance liquid 
chromatography of cellular supernatant. Next, Parkinsonian mice received the stem cell-
derived mesDA cells. Over the course of sixteen days, mice with delivered cells 
recovered from amphetamine-induced rotational asymmetry, whereas, untreated mice did 
not, confirming transplantation reversed Parkinson’s disease related symptoms and 
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behavioral changes. Electrophysiological measurements through whole-cell patch 
clamping revealed optogenetic stimulation of eNpHR3.0-YFP worked properly in vivo. 
Graft-to-host connectivity was then investigated. Corridor tasks were performed where 
animals explored a narrow corridor and collected sucrose pellets situated near each side 
of the walls. Control mice with no Parkinsonian-inducing lesion nor mesDA 
transplantation collected pellets from both sides equally. Parkinsonian animals 
(unilaterally lesioned) showed preference to pellets on the same side (ipsilateral) where 
the lesion occurred. Interestingly, lesioned animals exhibited inverted responses 
(contralateral) when apomorphine, a dopamine-receptor-agonist that signals through 
lesion-sensitized dopamine receptors on medium spiny neurons (MSNs) and striatal 
interneurons. Unilaterally lesioned animals that received mesDA transplantation, showed 
preferences contralateral to the lesion, showing recovery from Parkinsonian behavior. 
However, mice with optogenetic stimulation of eNpHR3.0-YFP changed the response to 
ipsilateral; light stimulation on control and YFP mice showed no significant change. To 
ascertain whether termination of dopamine release was solely responsible for this 
recovery from disease-related behavior, apomorphine was administered to mice prior to 
optogenetic testing. Apomorphine blocked the ipsilateral effect of eNpHR3.0-YFP-
mediated silencing; however, complete contralateral motor effects were not observed as 
before. 
1.3.4 Genetic Calcium Sensors 
Calcium is an essential element for living organisms since it is a major component 
of bone mineralization and cellular signal transduction. Significant engineering has made 
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genetic constructs that are capable of translating calcium ion concentrations into 
fluorescence (Figure 1.6). Such tools are necessary as calcium chemical dyes can have 
difficulty in penetrating animals such as C. elegans or Drosophila and cannot be targeted 
to cell types using tissue specific promoters [105]. A protein, termed GCaMP, contains a 
circularly permutated EGFP molecule (cpEGFP) that is fused to the M13 fragment of 
myosin light chain kinase on the N-terminus and calmodulin (CaM) on the C-terminus. 
Binding of Ca2+ to CaM and the M13 fragment induces a conformational change in 
cpEGFP causing increased fluorescence [106]. Although GCaMP is an effective tool in 
sensing calcium, its inferred calcium measurements are sensitive to the levels of 
expression of the protein and therefore its use could be limited in cases where there are 
genetic fluctuations or differences in DNA copy number per cell [105, 107]. An 
alternative genetic calcium sensor is yellow cameleon, which is based on Förster 
resonance energy transfer (FRET) of light from an excited cyan fluorescent protein (CFP) 
to yellow fluorescent protein (YFP) [108]. The CFP and YFP molecules are separated by 
the calmodulin M13 fragment. When calcium is not bound to the M13 portion of yellow 
cameleon, the emitted light from excited CFP cannot reach YFP effectively; however, a 
conformational change resulting from calcium binding can bring the fluorescent proteins 
close enough for successful FRET and emission of yellow light detectable by 
fluorescence microscopy. By using FRET, calcium levels are indicated by the ratio 
between CFP and YFP and thus are insensitive, in principle, to fluctuations in protein 
expression [105, 107]. Similarly to yellow cameleon, Troponin C-based calcium ion 
sensor proteins rely on FRET between cyan and yellow fluorescent proteins; however, 
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the calcium-mediated conformational change is induced by calcium binding to Troponin 
C rather than the M13 fragment and calmodulin [109]. This sensor reduced the number of 
calcium binding sites, lowering cooperative binding dynamics, thus generating more 
linear responses to calcium. However, one downside to using FRET-based calcium 
sensors is that a larger spectral range is used owing to the use of two fluorescent proteins 
than one, thereby making multi-color experiments more difficult to design and implement 
[105]. 
Exemplary Case 1: Kidney disease 
Chronic kidney disease can result from dysfunction of the glomerulus. Podocytes 
are a glomerular cell type that are important in maintaining normal structure and function 
of the glomerular filtration barrier. They can decrease glomerular filtration rate through 
cytoskeletal contraction, causing closure of filtration slits. Calcium’s critical role in 
podocyte motility via regulation of actin dynamics and Rho GTPases supports evidence 
that increased podocyte intracellular [Ca2+] is linked to podocyte pathology. As tracking 
in vivo cellular calcium using calcium-sensitive chemical probes represents a technical 
challenge, a study used GCaMP3 genetically targeted to podocytes to study the 
relationship between calcium ion concentration and glomerular damage [110]. 
GCaMP3 was targeted to podocytes by crossing a mouse carrying Cre 
recombinase driven by a podocin promoter with a lox-stop-lox-GCaMP3 mouse, referred 
to as Pod-GCaMP3 mice. Time-lapse multiphoton microscopy (MPM) was used to to 
visualize the intact kidney. MPM revealed low GCaMP3 expression, and thereby low 
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[Ca2+], in healthy podocytes. After subjecting animals to Angiotensin II, a known trigger 
of increased [Ca2+] in podocytes, a small, but significant increase in [Ca2+] was seen by 
GCaMP3 fluorescence. Stimulation by an Angiotensin II receptor blocker, losartan, 
prevented calcium increases by Angiotensin II. A new technique to elicit podocyte 
damage included the use of short pulse of focused laser light to single podocytes, 
inducing a significant increase of GCaMP3 fluorescence and leakage of albumin from the 
plasma into the Bowman’s space. Imaging further revealed podocyte injury-induced 
[Ca2+] waves around the primary sites, indicating cell-to-cell propagation of calcium ions. 
Similarly, mechanically-induced podocyte damage by perturbation by a glass 
micropipette resulted in similar cell-to-cell calcium propagation waves. Two previously 
established disease mouse models were examined using this novel live calcium imaging 
technique: renal fibrosis (unilateral ureteral obstruction [UUO]) and focal segmental 
glomerulosclerosis (FSGS). In the UUO model, GCaMP3 fluorescence increase over 10-
fold over time as compared to fluorescence from podocin-driven GFP control mice, 
which remained unchanged during the course of the experiment. Results for the 
aggressive FSGS model yielded a two-fold increase in GCaMP3 fluorescence, though 
imaging could only be performed through the first four days after induction due to the 
rapidly developing pathology in this cytotoxic IgG-induced model. 
Exemplary Case 2: Alzheimer’s Disease 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease that is 
characterized by the presence of senile plaques and accounts for the majority of dementia 
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cases. The role of intracellular calcium, [Ca2+]i, has been implicated in the pathogenesis 
of Alzheimer’s disease. A group utilized yellow cameleon 3.6 (YC3.6) together with 
multiphoton imaging to measure calcium ion concentration of individual neurons in vivo 
of an Alzheimer’s disease mouse model as small-molecule calcium indicators are 
experimentally challenging [111]. YC3.6 was packaged into adeno-associated viruses and 
transduced into neocortices of wild type (WT) and transgenic adult mice. Transgenic 
mice included those with single or double mutations of amyloid precursor protein (APP), 
a protein whose proteolysis creates beta-amyloid, the primary component of amyloid 
plaques; and presenilin 1 (PS1), a subunit of gamma secretase that mediates release of 
beta-amyloid. The APP “Swedish mutation” (APP-KM670/671NL or APP[Swe]) leads to 
development of beta-amyloid plaques at ~14-15 months of age, whereas, the double 
mutations of APP(Swe) with PS1-DE9 yields plaques at a much earlier age of 4.5-5 
months. Neither PS1-DE9 nor PS1-M146V generated beta-amyloid plaque pathology. 
Calcium measurements via YC3.6 were calibrated by variation of applied extracellular 
calcium ions to YC3.6-expressing CHO cells in presence of calcium ionophore, 
ionomycin. The average resting intracellular calcium ion concentrations of all 
morphologically normal spiny and aspiny processes of WT mice transduced with YC3.6 
was determined to be 77nM; injection of glutamate by pipette to dendrites evoked a 
three-fold increase in [Ca2+]i. Calcium overload was defined to be an [Ca2+]i two standard 
deviations above the mean of neurites from nontransgenic mice (147nM). Calcium 
determination via YC3.6 revealed two separate populations in APP/PS1 double mutant 
mice; one population similar to WT with mean of [Ca2+]i = 77 nM and a second broad 
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population encompassing calcium ion concentrations between 162-1535 nM with a mean 
of 499 nM. In contrast, younger APP/PS1 mutant mice that did not yet succumb to plaque 
development had calcium overload in 2.3% of neurites compared to 20.2% in the older 
APP/PS1 mice with plaques. PS1 mutations alone did not yield appreciable calcium 
overload compared to controls, though APP(Swe) mice exhibited severe calcium 
overload of 22%. This suggests that although PS1 mutations accelerate pathological 
progression in presence of APP(Swe), they are not sufficient to induce calcium overload. 
By using a beta-amyloid binding dye, methoxy-O4, it was determined that beta-amyloid 
plaques act as focal sources of toxicity leading to elevated [Ca2+]i in 30% of neurites 
within 25 µm compared to 17% of neurites further away. Upon manual image-based 
inspection of [Ca2+]i in spines and dendrites of neurons, it was found that calcium 
overloaded neurons had a strong correlation between spine and dendrite calcium (R2 = 
0.77 and slope = 0.85) versus neurons with normal calcium levels (R2 = 0.26 and slope = 
0.51), indicating disrupted spino-dendritic compartmentalization in calcium-overloaded 
cells. Furthermore, about half of calcium-overloaded neurites demonstrated beaded, 
blebbed, or dysmorphic processes, which are rarely seen (<1.5%) in WT mice or non-
overloaded neurites of transgenic mice. Finally, the authors questioned whether the 
abnormal neuritic beading morphology, and its corresponding elevated [Ca2+]i, could be 
antagonized by blocking Ca2+/calmodulin-dependent calcineurin (CaN) through 
administration of CaN inhibitor FK506. Corroborating their hypothesis, FK506-treated 
animals exhibited reduced number of beading and severe calcium overloading. 
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1.4 Conclusions and Future Prospective 
Cells leverage their complex molecular and genetic networks to accomplish 
critical tasks. Improper rewiring of these networks often causes disease. Much of the 
synthetic biology efforts used to study disease mechanisms are examples of reverse 
engineering approach that study individual networks and components in detail, often 
through knocking out or overexpressing key genes at the right cell types and at the right 
time. This approach has provided many valuable insights into the property of the system. 
However, endogenous genetic networks are usually embedded within larger 
interconnected networks that are vital for the cell. As such, some governing rules for any 
particular disease system are difficult to uncover using the reverse engineering approach. 
In contrast, a forward engineering approach where a given phenotype is recreated based 
on a set of design rules would allow direct investigation of core basic design 
requirements. Over the years, synthetic biology has followed this forward engineering 
approach to explore the design rules on many sophisticated synthetic genetic devices, 
such as genetic toggle switches [9], oscillators [112-116], multi-input logic gates [18, 19, 
117], classifiers [38, 118], and "secrete-and-sense" circuits [119]. For instance, the initial 
oscillator design employed a repressor-based ring network and displayed a high degree of 
cell-cell variability [25]. Subsequent oscillator designs based on interlinked positive and 
negative feedback loops showed much improved robustness [115]. Although done by 
different labs, these efforts allow comparison of different oscillator designs, which would 
not have been possible using the reverse engineering approach. In addition, synthetic 
circuits can be repurposed for practical applications in therapeutics, drug-discovery, 
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biomolecule sensing and production, and bioremediation. The Hasty lab used their 
synthetic oscillators to sense arsenic via modulation of the oscillatory period, which 
enhanced performance in a noisy cellular environment [114, 120]. The forward 
engineering approach is primed for application to disease related genetic networks, which 
will provide a unique opportunity to bridge basic medical and applied science. 
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1.4 Figures 
 
Figure 1.1: Site-specific recombinase tools for organism disease modeling. 
(a) Common circuit topologies for site-specific recombinase gene activation or gene knockout. (top) 
For gene activation, a transcription termination sequence surrounded by recombination sites is placed 
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before the targeted gene. Without the presence of a recombinase, gene expression is blocked by the 
transcription termination sequence. After recombinase-mediated deletion of the termination sequence 
between the recombination sites, the gene is now activated. (bottom) Gene knockout can be achieved 
through placement of recombination sites around a gene of interest. The gene is removed from the 
genome upon recombinase-mediated DNA deletion. (b) Control of site-specific recombinase activity 
for spatiotemporal modulation of gene expression. (top) Another control strategy utilizes tamoxifen, 
and its downstream metabolite 4-hydroxytamoxifen (4-OHT), for small molecule-mediated 
translocation of a recombinase fused to a mutated estrogen receptor (ERT2) from the cytoplasm to the 
nucleus. (bottom) Recombinase activity can be controlled through administration of a 
heterodimerization agent, such as a rapamycin-derivative or blue-light, to bring together two inactive 
recombinase halves for reconstitution of activity. (c) Site-specific recombinases are often 
implemented into animal disease models for conditional gene expression or knockout. (top) For tissue-
specific gene expression, a recombinase driver mouse that contains a site-specific recombinase 
restricted to a tissue via a tissue-specific promoter is crossed to a “lox-stop-lox” recombinase reporter 
mouse that expresses the gene of interest only upon presence of the recombinase. After crossing the 
two mice, gene expression is now restricted to the desired tissue. (bottom) Tissue-specific knockout of 
a gene can be similarly achieved through crossing of a driver mouse with a reporter mouse that 
contains a floxed gene of interest. 
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Figure 1.2: A novel dual recombinase system can be used for modeling of cancer in mice. 
(a,b) Traditional means of inducing pancreatic cancer through restricted KrasG12D oncogene 
expression in Pdx1+ cells through a Cre or Flp system. (c) The traditional oncogene activation system 
was extended through the use of two recombinases. Flp recombinase restricts genetic perturbations to 
Pdx1+ cells. Spatiotemporal control of Cre-ERT2 recombinase is used for inactivation of tumor 
suppressor genes to examine their role in tumor progression, and for activation of diphtheria toxin 
fragment A (DTA) for treatment modeling of tumor reduction. 
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Figure 1.3: Precise genome-editing and modifications through the RNA-guided CRISPR/Cas9 
endonuclease system. 
(a) S. pyogenes Cas9 endonuclease in complex with sgRNA and DNA. A double-stranded break is 
created a few nucleotides adjacent to the Protospacer Adjacent Motif (PAM) sequence. (b) (left) Cas9 
can be used to generate targeted double-stranded breaks in the genome for error-prone creation of 
insertions or deletions by non-homologous end joining (NHEJ) or precise DNA insertions via 
integration of donor DNA via homology directed repair (HDR). (right) Nickase Cas9 (nCas9) can be 
used to created single-stranded nicks in the genome. Utilization of two nearby nicks can lower chance 
of off-target DNA integration. (c) A catalytically dead Cas9 (dCas9) can be used solely for its precise 
DNA-binding capabilities. Fusion of dCas9 to transcriptional activation domains (AD), such as 
Herpes Simplex Viral Protein 16 (VP16), can be used for targeted gene expression elevation. 
Conversely, fusion of dCas9 and a transcriptional repression domain (RD), such as Krüppel associated 
box (KRAB), can lead to reduced levels of gene expression. Multiple sgRNAs targeting a particular 
gene can enhance expression; furthermore, the multiplexing capacity of the CRISPR/Cas9 system can 
be utilized, permitting targeting modifications to multiple genes, simultaneously. 
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Figure 1.4: Chemical genetics tools for biological manipulation and study. 
(a) Chemical dimerization tools can be used for powerful strategies of protein regulation. 
Heterodimerization can reconstitute activity of a split protein or induce new functionalities. Small 
molecule homodimerization of caspase molecules can be used for inducible cell death. (b) Addition of 
a chemical-responsive degradation domain to a protein of interest induces proteolytic degradation in 
the absence of a stabilization molecule; adding the molecule restores protein stability and 
functionality.
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Figure 1.5: Light sensitive membrane proteins for optogenetic cellular control.  
Channelrhodopsins are activated by blue light and cause cellular hypopolarization through entrance of 
sodium ions into the intracellular space. Halorhodopsins and Archaerhodopsins utilize yellow-light for 
cellular hyperpolarization by entrance of chloride ions or exit of hydrogen ions to or from the cell, 
respectively. Green-light excitable OptoXR membrane proteins enable control of intracellular signal 
pathways, such as the cyclic AMP and IP3 pathways. 
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Figure 1.6: A variety of genetic constructs can be used for quantitative in vivo calcium 
monitoring for determination of calcium’s role in disease formation and progression. 
(top) GCaMP is constructed from a fusion of a circularly permutated green fluorescent protein 
(cpGFP) molecule fused to both calmodulin (CaM) and a M13 peptide of the myosin light chain 
kinase. Binding of calcium to CaM and M13 induces a conformational change in cpGFP, resulting in 
increased GFP fluorescence. (middle) Yellow Cameleon utilizes a different mechanism based on 
Förster resonance energy transfer (FRET) that occurs between a cyan fluorescent protein (CFP) and a 
yellow fluorescent protein (YFP) upon CaM and M13 binding of calcium. (bottom) Rather than a 
calmodulin/M13/calcium binding interaction, Twitch utilizes a confirmational change in troponin C 
upon calcium binding to induce FRET between CFP and YFP molecules. 	
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CHAPTER TWO: High-Performance Inducible Recombinases 
2.1 Introduction 
Site-specific recombinases (SSRs) are enzymes that perform site-specific DNA 
recombination through their ability to carry out DNA-binding, cutting and ligation 
operations. SSRs can effectively regulate gene expression depending on the placement of 
the corresponding set of recombination sites around a gene of interest or transcription 
termination sequence. Furthermore, chemical and light-inducible systems have been 
engineered to control the expression or activity of SSRs, thus enabling spatiotemporal 
control of gene expression. Due to their unique chemistry, performance, and 
controllability, SSRs have been used extensively in genetic circuit designs [121-123] and 
organism model development [44, 48, 124] to interrogate many different biological 
processes and design principles. While inducible recombinases have proven to be 
invaluable in many studies [45, 125, 126], especially in mammalian cells, the number of 
orthogonal versions is limited. Most inducible systems are optimized solely for Cre 
recombinase and few, if any, orthogonal systems are available for other recombinases. 
This limitation constrains the sophistication of the genetics that can be developed and 
ultimately the biological and engineering problems that can be addressed. Furthermore, 
some small molecule inducers (e.g., antibiotics or hormone analogs) may not be 
compatible with some experimental objectives. As such, there is an urgent need to 
develop a large collection of inducible recombinases that employ an array of orthogonal 
inducers. 
A major challenge to developing novel inducible recombinases in mammalian 
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cells is to ensure high performance (a low basal activity with high induced activity), 
which requires orthogonal SSRs and inducible systems to work effectively together. This 
is not a trivial task because of the availability of diverse classes of SSRs and inducible 
systems. For instance, many SSRs have been identified from different organisms and can 
be broadly categorized into two main classes depending on their catalytic residue: 
tyrosine or serine. SSRs that utilize tyrosine include the tyrosine integrases, such as the λ 
and HK022 integrases, and the tyrosine recombinases, such as the Cre and Flp 
recombinases. SSRs that use a serine catalytic residue include: small serine 
recombinases, such as resolvases (e.g. ɣδ and Tn3), invertases (e.g. Gin and Hin), IS607-
type transposases (e.g. TnpA), and ISXc5-type resolvases (e.g. ISXc5); and large serine 
recombinases, such as large serine integrases (e.g. ɸC31, TP901 and Bxb1) and large 
serine transposases (e.g. TnpX and CcrA).  We, and others, have shown that many of 
these recombinases are active in mammalian cells, thus serving as a potential source for 
engineering orthogonal inducible recombinases. 
A number of inducible systems have been employed to control recombinase 
activity. Transcriptional regulation via the Tet-ON/doxycycline-inducible system has 
demonstrated functionality in driving Cre expression in mice[127]. However, this 
strategy removes the possibility of placing the recombinase under another conditional 
(e.g. tissue-specific) promoter. An alternative approach is to use post-translational control 
systems, which permit the usage of any promoter and garner speed benefits from the lack 
of transcriptional delay. An attractive post-translational system is the use of chemical-
inducible dimerization (CID) domains, whereby a protein of interest is split into two 
		
48 
protein fragments and fused to chemical-inducible heterodimerization domains. This 
system is advantageous because split proteins tagged with CIDs can be rendered non-
functional until the molecule is administered, yielding low basal activities. Thus, high 
levels of the protein can be overexpressed in the desired cellular compartment, enabling 
fast responses. This is in contrast to other post-translational systems that are either 
actively degrading the protein until a drug is administered to stabilize it[128] or 
relegating the protein to an undesired location until drug exposure to translocate it[33, 
129]. 
The first CID system was derived from the rapamycin (mTOR) signaling pathway 
was developed. In this system, a member of the mTOR pathway, FKBP, forms a 
heterodimer with the FKBP-rapamycin-binding (FRB) domain of the mTOR protein upon 
simultaneous rapamycin binding. To remove reliance on the natural rapamycin molecule, 
FKBP and FRBT2098L can be heterodimerized by rapamycin analog, AP21967, termed 
“rapalog.” An alternative and more reversible chemical dimerization system was 
discovered that uses plant phytohormone abscisic acid that can be washed out [79]. 
Finally, a system based on plant hormone gibberellin was used in conjunction with the 
rapamycin system to permit multiplexed and logical control of cellular processes [80, 81]. 
In this work, we address the major shortage of inducible recombinases by 
developing a large suite of inducible recombinases through screening for functional split 
locations to use with the rapalog, abscisic acid, and gibberellin CID systems. In total, we 
were able to achieve functional chemical induction in seven recombinases from both 
tyrosine and serine families. We perform detailed characterizations of select 
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recombinases for benchmarking purposes and quantitative comparison. Moreover, we 
engineered two light and temperature inducible recombinases for minimally invasive 
conditional recombination. Finally, we demonstrate the functionality of the systems in the 
form of protein and DNA-based logic gates.  Together, our library of characterized 
inducible recombinases will enable the creation of novel genetic circuits and animal 
models for fundamental studies and biotechnological applications. 
2.2 Results 
2.2.1 Selecting Split Locations 
We sought to utilize CID systems for small-molecule control of recombinases. 
We chose four recombinases from the tyrosine recombinase family, including two from 
phage (Cre and VCre) and two from yeast (Flp and B3), and three from the large serine 
integrase family (ɸC31, TP901 and Bxb1). These were chosen due to their high activity 
in mammalian cells and orthogonality. Potential splits sites were determined by analyzing 
primary and secondary sequences. Crystal structures were available for Cre (PDB: 1XO0) 
and Flp (PDB: 1FLO) recombinases and were utilized to determine secondary structure 
of analogous VCre and B3 recombinases through HHPred alignment (Figures 2.1 and 
2.2). Secondary structure annotations for serine integrases was determined through from 
a literature source [130] that utilized TP901 integrase N-terminus domain structure and 
A118 integrase C-terminus domain structure. In general, split sites were chosen to avoid 
secondary structures and catalytic residues as we hypothesized introducing CID domains 
into these locations could permanently disrupt these structures and their roles in 
recombination (DNA-binding, cleavage, exchange and ligation); however, we chose 
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many within these structures in Cre recombinase to counter-test this hypothesis. After a 
split location (S) was chosen, a “starting fragment” was cloned from the N-terminus of 
the protein (beginning from the starting methionine in DNA) to S and a “terminating 
fragment” from S+1 to the C-terminus of the protein (to the last basepair in DNA). 
Fragments were inserted into vectors that contain sequences to code for flexible glycine 
and serine-rich linkers, nuclear localization signals, and CID domains (Figure 2.3). For 
the rapalog (RAP) system, FRB and FKBP CID domains were used; abscisic acid (ABA) 
system, PYL and ABI; and gibberellin (GIB) system, GID1 and GAI. 
2.2.2 Screening for Small-molecule Inducible Dimerization 
Screens for identifying functional split locations in tyrosine recombinases were 
performed using the GIB system as preliminary testing yielded more promising 
performance over the other two systems (Figure 2.4). In total, 42 locations were tested 
for Cre recombinase, 20 for Flp, 20 for VCre, and 28 for B3.  The RAP system worked 
better for large serine integrases and was used for 13 splits of ɸC31 and 11 for TP901; 
GIB was used for two Bxb1 split locations (Figure 2.5). 
A variety of responses were found: “functionally dead,” yielding no activity with 
or without addition of the drug; “constitutively active,” partial or full recombination with 
no significant dependency on the drug; and “responders,” that saw a mild to strong 
dependency on the drug. A majority of the splits fall into the “functionally dead” 
category and these are thought to yield no activity due to improper formation of 
complexes ripe for recombination. In these cases, CID domains may have been inserted 
into places critical for recombination processes or addition of CID domains caused too 
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much three-dimensional contortion to perform recombination. Some locations yielded 
“constitutively active” responses, where CID domains played little or no role in inhibiting 
and activating recombination. These configurations may splice off a region of the 
recombinase that may not be critical for a full recombination response. Moreover, 
resultant split halves of the recombinase could have enough self-association or 
complementation by DNA-binding to elicit a drug-independent response as well. Finally, 
some were successful “responders,” which triggered drug-dependent responses. Within 
this group, a select few “good responders” yielded high fold-activations with high GFP in 
the “on” state and low GFP in the “off” state. However, some less desired 
“poor/moderate responders” produced low levels of GFP expression in the “on” state or 
high levels of GFP in the “off state.” 
Despite each recombinase having analogous structures, with Cre identifying 
closest to VCre and Flp to B3, successful split locations did not seem show significant 
correspondence between recombinases. Despite the large number of splits screened for 
B3, only two were found to garner any appreciable drug-dependent response. 
Interestingly, for Flp, B3, ɸC31, and Bxb1, some locations that yielded strong drug-
dependent responses were surprisingly close (<35 amino acids) to either the N-terminus 
or C-terminus; therefore, underlying the importance of the native protein structures in 
these terminal areas for recombination. Of the seven Cre splits (S = 190, 251, 184, 144, 
270, 229, and 256) that yielded fold changes over ten, two (S = 144 and 270) were within 
secondary structures. Overall, 2 out of 19 (10.52%) of Cre splits within secondary 
structures yielded fold changes over ten, and 5 out of 23 (21.74%) Cre splits outside 
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secondary structures yielded fold changes over ten. Four of the best performing Cre GIB 
candidates were compared against a split location determined from a previous work [35] 
where amino acids 19-59 were used for the “starting fragment” and 60-343 for the 
“ending fragment.” Despite placing GID1 and GAI domains at varying N-terminal or C-
terminal configurations for the 19-59/60-343 split, none were close in reaching the low 
“off” and high “on” responses of the newly identified splits using just a single orientation 
of CIDs (Figure 2.6). 
2.2.3 Domain Swapping and Benchmarking Performance 
To gain better insight into the functionality of some of the inducible 
recombinases, quantitative cytometric analyses were performed to characterize 
performance between recombinase systems, plasmid dosage, and time. Fluorescence 
channel measurements were converted to units of molecules of equivalent fluorescein, a 
standard used to normalize measurements across instruments and fluorescent molecules. 
Analyses focused around splits 270, 27 and 233 of Cre, Flp and ɸC31, respectively, with 
all three CID systems. In addition, the comparison included a commonly used system, 
whereby Cre is fused to a mutated estrogen receptor (ERT2); this complex remains in the 
cytoplasm until addition of 4-hydroxytamoxifen (4OHT), which induces translocation to 
the nucleus and resulting site-specific recombination. A signal-to-noise (SNR) metric was 
used to evaluate how strongly the plus and minus drug cases can be distinguished from 
each other; better separation between signals involves both a higher absolute difference in 
mean fluorescence intensities but also a lower spread of fluorescence values (noise) 
within those cell population distributions (Figure 2.7a). Between recombinase systems, 
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ɸC31 integrase yielded the highest SNR values; this could be attributed to the “quieter” 
reporter that is used that necessitates the complete inversion of the GFP sequence; this is 
in contrast to using a polyA deletion strategy in the case of tyrosine recombinases, which 
yields low but detectable amount of read-through for highly-transfected cells. Across 
plasmid dosage as measured by transfection marker expression level, SNR values 
generally increased as “on” state GFP measurements grew due to increased copies of 
reporter; however, in the case of Cre and Flp RAP systems, SNR reached a maximum 
and then declined due to “leaky” recombination and noisier GFP expression in the “off” 
state. Over a time course of 100 hours, leaky “off” behavior was especially apparent in 
Cre RAP, Cre 4OHT, and Flp RAP systems, which yielded high SNR values early on, but 
began to decline after 21 hours (Figures 2.7b through 2.7d). The GIB system 
consistently resulted in strong performance between the three recombinases and all three 
systems for ɸC31 integrase. 
An advantage of identifying viable split locations is that they can be implemented 
into newly discovered dimerization systems. Four splits for Cre, four for Flp, three for 
VCre and four for ɸC31 having moderate to good responses from the initial screens were 
selected to swap for the remaining CID domains (Figures 2.7e through 2.7l). In general, 
swapping dimerization domains between GIB/RAP/ABA domains or domain orientations 
for the case of Flp recombinase (Figure 2.8) yielded drug-dependent responses for the 
selected split sites; however, many tyrosine recombinase split locations using the RAP 
system yielded surprisingly high levels of recombination without addition of the drug, 
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converting good responders with the GIB system into near constitutively active systems 
with RAP. 
2.2.4 Light and Temperature Inducible Dimerization 
A variety of light-inducible dimerization (LID) systems are available for 
applications that necessitate minimally invasive and precise stimulation. Here, we chose 
to use a blue LID system, termed “Magnet”, which uses heterodimerization domains 
(pMag and nMag) engineered from the blue light photoreceptor VVD from the 
filamentous fungus Neurospora crassa. A programmable blue-light emitting device was 
used to induce four splits of Cre or Flp that use the pair of Magnet LIDs (Figure 2.9). In 
addition, a construct that expresses an established [131] Cre Magnet (termed PA-Cre) 
using the 19-59/60-343 split was tested in parallel. Sixty-second blue light pulses were 
administered every hour over a 24-hour period, 18-hours post-transfection. Blue-light 
inducible dimerization was achieved for all constructs for Cre and Flp, albeit with 
different performances amongst splits. Serendipitously, it was found that exposing the 
cells to colder temperatures could also induce recombination, in some cases more than 
blue light. Temperature induction was performed by exposing the cells to either room 
temperature (22°C) or refrigerated (4°C) conditions for four hourly 15-minute pulses 18 
hours after transfection. The temperature sensitivity of this system may not be completely 
surprising as VVD has been found to play a role in temperature regulation [132, 133] and 
others have engineered another closely related blue LID system to be more sensitive to 
colder temperature [134].  
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2.2.5 Protein and DNA-based Logic 
With this large repertoire of inducible recombinases capable of responding to 
different drugs and having various functional split locations, we theorized we could 
generate multi-input logic gates. The first approach taken was to use multiple CIDs 
within one recombinase protein. Flp recombinase was split into three segments using two 
functional split locations found previously (S1 = 27, S2 = 396); the GIB and ABA CID 
domains were utilized for small-molecule mediated assembly of this tripartite double split 
complex (Figure 2.10a). A strong response was found only when both gibberellin and 
abscisic acid were administered, demonstrating a 2-input AND gate functionality (Figure 
2.10b); however, this did not work for another pair (S1 = 168, S2 = 396) of vetted split 
locations (Figure 2.11). A second approach taken to achieve multi-input logic operations 
was to use multiple inducible recombinase systems and integrate those signals with a 
multi-input reporter DNA plasmid (Figure 2.10c). We chose to use three inducible split 
recombinase systems and a 4OHT-inducible Cre construct. These signals were then 
integrated using a 4-input AND gate reporter where GFP is expressed only when two 
termination sequences are deleted and both promoter and GFP sequences are inverted. 
All combinations of drugs were applied to the cells and the highest GFP expression was 
found when all four drugs were applied together (Figure 2.10d). 
2.3 Discussion 
In this work, we have greatly increased the number of inducible recombinase 
systems available in mammalian cells. We demonstrated the first successful splitting of 
Flp, VCre, B3, ɸC31, TP901 and Bxb1 recombinases and reconstitution of functionality 
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with chemical-inducible dimerization systems; this vastly enhances the usage of these 
recombinases, as few or zero inducible systems were available prior. Additional split 
locations in Cre recombinase were found to yield higher performance than a previously 
recognized location; using the new split locations, we demonstrate the first gibberellin 
and abscisic acid inducible Cre systems. Using viable split locations of Cre and Flp 
recombinases, we incorporate the blue-light inducible Magnet heterodimerization system 
and show the first demonstration of light-inducible Flp recombination. Moreover, we 
found that we could use a reduction of temperature rather than light illumination to 
induce recombination with this system, providing another way of conditionally activating 
recombinase responses in a minimally invasive fashion. 
Not only did we find single functional split locations, we found multiple viable 
candidates for most recombinases. Interestingly, each location yielded a different degree 
of performance depending on which CID system was utilized. For instance, Cre Magnet 
(S = 270) yielded surprisingly low sensitivity to blue light despite this split location 
having strong performance amongst other tested Cre splits using the CID domains. This 
finding underlies the importance of finding multiple functional split locations for each 
protein as they may behave differently per introduced dimerization domain. Moreover, 
the usage of multiple sites within one protein permits creation of multi-input logic gates. 
We demonstrate this idea with a doubly split Flp construct that requires both the addition 
of the abscisic acid and gibberellin compounds to function. A tripartite complex such as 
this will be especially useful for intersectional targeting of cells. Each of the three 
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fragments could be individually expressed by different promoters; thereby, further 
tightening the desired spatial and temporal targeting of recombination.    
2.4 Conclusion 
We have created the largest library of well-curated inducible recombinases in 
mammalian cells. Due to the high prevalence of site-specific recombinase technology in 
the biological sphere, we look forward to seeing the many applications and discoveries 
that will come about using our inducible recombinase systems. Our work was enabled by 
the numerous recombinase and dimerization systems available; thus, we encourage the 
further development of these tools. Newly discovered recombinases are being 
increasingly isolated[15], better high-throughout DNA-assembly techniques could 
provide faster and automated split site identification capabilities, and ligand-responsive 
dimerization domains are waiting to be found or engineered. 
2.5 Methods 
2.5.1 Protein Structural Analysis and Identification 
Secondary structure assignments for Cre and Flp were obtained from Protein 
Database (PDB) crystal structures, 1XO0_A and 1FLO_A, respectively. HHPred[135] 
was utilized to predict secondary structures for VCre and B3 using Cre and Flp crystal 
structure data. JPred4[136] was used to predict secondary structures of a stretch of amino 
acids (423 through 568) for B3 recombinase. ASAView[137] was used to obtain absolute 
solvent area (solvent accessibility) from Cre and Flp crystal structures. Secondary 
structure assignments for serine integrases ɸC31, TP901 and Bxb1 were adapted from a 
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literature source[130]. 3D crystal structure images were created using Visual Molecular 
Dynamics software package. 
2.5.2 DNA Assembly 
A series of sub-cloning vectors containing CID or LID domains were assembled 
using standard molecular cloning techniques or Gibson isothermal assembly. For each 
CID or LID, two sub-cloning vectors were made such that a recombinase could be tagged 
with the domain on the C-terminus or N-terminus and a glycine-serine rich linker L1 
(SGGSGSGSSGGSGT). For insertion into a C-terminal CID or LID sub-cloning vector, 
recombinase “starting fragments” were first PCR-amplified out of a full recombinase 
sequence template to contain a 5’ sequence to code for an MluI restriction site and a 
Kozak consensus sequence, and a 3’ sequence to code for a BspEI restriction site. These 
PCR fragments were then isolated using agarose gel extraction and purification (Epoch 
Life Science). Finally, the isolated fragments were digested with MluI and BspEI 
restriction enzymes (New England Biolabs), purified by PCR cleanup (Epoch Life 
Science) and ligated into an MluI/BspEI-digested CID and LID sub-cloning vectors that 
were isolated by PCR cleanup (Epoch Life Science). Reaction products were transformed 
into chemically competent Top10 E. coli cells and selected on LB-agar plates with 
carbenicillin at 37°C static conditions. Colonies were picked the following day, 
inoculated into carbenicillin-containing LB medium, and grown in a 37°C shaking 
incubator (Infors). Once the cells were near or at stationary phase, plasmid DNA was 
isolated using mini plasmid preparation (Epoch Life Science). Analytical digests with 
MluI/BspEI were performed and run on gel electrophoresis to assay if a correct product 
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was made. Plasmid clones with correct gel bands were sent for sequencing (Quintara 
Biosciences). For insertion into a N-terminal CID or LID sub-cloning vector, 
recombinase “terminating fragments” were first PCR-amplified out of a full recombinase 
sequence template to contain a 5’ sequence to code for a KpnI-HF restriction site and a 3’ 
sequence to code for an SV40 nuclear localization signal, stop codon, and an EcoRI-HF 
restriction site. A similar process was followed as before with the C-terminal CID and 
LID sub-cloning vectors; however, KpnI-HF and EcoRI-HF restriction digests (New 
England Biolabs) were carried out rather than with MluI and BspEI. To swap between 
CID and LID domains, sequenced fragments were gel-isolated from sequenced vectors 
using MluI/BspEI or KpnI-HF/EcoRI-HF and inserted into corresponding CID or LID 
sub-cloning vectors. Occasionally, the BspEI site was blocked by dam methylation and 
PCR fragments were utilized instead. The extra central fragment for the trimeric Flp 
system was created with two different linkers L1 and L2 (GPAGGGSGGGSGGPAG) 
separating the Flp “central fragment” from the CID domains. 
2.5.3 Maintenance and Transient DNA Transfection of HEK293FT Cells 
HEK293FT cells were kept in a static 37°C humidified incubator with 5% CO2, 
except for specified periods during temperature induction. Cells were maintained in 
DMEM medium (Corning) containing 5% fetal bovine serum (ThermoFisher), 50 UI/mL 
penicillin and 50 µg/mL streptomycin mixture (Corning), 2 mM glutamine (Corning) and 
1mM sodium pyruvate (Lonza). A polyethylenimine (PEI) protocol was followed to 
transfect HEK293FT cells. A master stock of PEI was made by dissolving linear PEI 
(Polysciences Cat. No. 23966-2) in deionized water at a concentration of 0.323g/L. 
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Concentrated hydrochloric acid was used to drop the pH to 2-3 while stirring to ensure 
complete dissolution; sodium hydroxide was added over time to bring the pH to 7.5. The 
final solution was filter-sterilized (0.22 µm), aliquoted, and stored at -80°C. For 
transfections, HEK293FT cells were plated (250 µL) in tissue culture-treated 48-well 
plates (Fisher Scientific) one or two days prior such they would be 50-70% confluent on 
the day of transfection. For most induction experiments in this work, 2000 ng (at 
50ng/µL) of DNA was prepared with specific combinations of plasmids and brought up 
to a volume of 100 µL using 0.15 M sodium chloride (NaCl, Fisher Scientific). Next, a 
PEI/NaCl mixture of 16 µL PEI stock and 84 µL NaCl, was mixed with the DNA-NaCl 
solution and incubated at room temperature for at least ten minutes. Finally, 25 µL of this 
solution was carefully added to each well of cells that were to be assayed; three wells for 
non-treated cells and three wells for drug or light-treated. For time-course experiments, 
this was similarly followed, rather with eight times the amount of each component prior 
to dispensing of 25 µL into each well. 
2.5.4 Small-Molecule Chemical Induction 
1000X stocks of abscisic acid (100mM, Gold Biotechnology Cat. No. A-050-500) 
and gibberellin ester (10mM, Toronto Research Chemicals Cat. No. G377500) were 
made in 100% ethanol and stored at -20°C. A 1000X stock of rapalog (A/C 
heterodimerizer AP21967) was obtained commercially (0.5mM, Clontech Cat. No. 
635056) and stored at -20°C. A 1000X stock of 4-hydroxytamoxifen (1mM, Sigma 
Aldrich) was made in methanol and stored at -20°C or -80°C. These molecules were 
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carefully added to cell cultures such that the final concentration was 1X at the time of 
induction. 
2.5.5 Light Illumination and Temperature Induction 
A modified large blue light transilluminator (IO Rodeo) was used in order to 
illuminate samples with 470 nm light. In order to control the timing and duration of light 
exposure, the included 18V wall adapter was cut and exposed leads were used to power 
both an ARDUINO® UNO microcontroller and the light array. The negative terminal of 
the array was connected to the collector of two NPN N2222 transistors in parallel. The 
signal pins of each transistor were then connected to pin 9 of the microcontroller. The 
UNO was programmed to send a signal through pin 9 to the transistors, activating the 
light box for a set duration at specific time intervals (e.g., turn on for one minute once 
every hour). PWM Pin 9 was used so that one could turn on the array at varying 
intensities. At maximum intensity, the light array achieved an illumination of 1 mW/m2 
as measured by a photodiode power sensor (S120C, Thorlabs). 
In order to adjust the timing and intensity of light exposure, an HC-06 
ARDUINO® Bluetooth module was installed, allowing the device to communicate with 
an AndroidTM smartphone application made with MIT App Inventor. The applications 
contain five entry boxes, allowing the user to set the length of exposure, time between 
exposures, number of exposures, the delay time before the exposure cycles began, and the 
relative intensity of the LED array. 
Samples that were to be illuminated were placed onto the light array directly after 
transfection and a sheet of aluminum foil was used to cover the entire apparatus. The 
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plates not treated for light illumination were wrapped in aluminum foil directly after 
transfection. These “dark” plates were either kept constantly in the 37°C incubator until 
flow cytometry or removed starting at 18 hours post-transfection and placed outside the 
incubator at room temperature or in a refrigerator at 4°C; these temperature pulses were 
performed four times, once every hour for fifteen minutes. 
2.5.6 Flow Cytometry 
For all experiments, except for given times during time-course experiments, plates 
were removed from the incubator two days post-transfection. Cells were trypsinized 
using 0.05% trypsin/0.53 mM EDTA (Corning) and resuspended with cell culture 
medium to a volume of 200 µL in 96 U-bottom plates. All cell populations were analyzed 
using a ThermoFisher Attune Nxt cytometer equipped with four lasers. GFP was detected 
using a 488 nm blue laser and a 510/10 bandpass emission filter; a 530/30 bandpass filter 
was used for experiments that converted to MEFL units. mTagBFP was detected using a 
405 nm violet laser and 440/50 bandpass emission filter. iRFP720 was detected using a 
638 nm red laser and 720/30 bandpass emission filter. Experiments in Figure 2.7 were 
analyzed using TASBE Flow Analytics, an open source flow cytometry software 
tool[138, 139]. In short, fluorescence channel measurements were converted to units of 
MEFL using 8-peak rainbow beads (Spherotech RCP-30-5A) and using linear color 
translation and compensation between fluorophores. Gaussian mixture models were used 
to isolate viable cell populations. Results were analyzed above a cutoff of a 106 MEFL on 
the constitutive transfection marker. For all other experiments, results were analyzed 
using FlowJo 9 (TreeStar). An FSC-A/SSC-A gate was used to remove debris from the 
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mammalian cell populations. An mTagBFP fluorescent protein was used as a transfection 
marker and positive BFP cells were first gated and mean GFP fluorescence was 
determined afterwards. 
2.5.7 Statistical Methods 
All transient gene expression experiments involved transfection of DNA into n = 
3 separate cell cultures. Fluorescence intensities for each cell culture population was 
averaged and the s.e.m. or s.d. was taken as noted. 
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2.6 Figures 
 
Figure 2.1: HHPred alignment of VCre to Cre. 
Results from VCre HHPred alignment to Cre recombinase (PDB: 1XO0, chain A) are reproduced here 
with additional annotations indicating split locations, catalytic residues, and secondary structure 
names adapted from a literature source[140]. Three-dimensional structure of Cre recombinase is 
plotted with beta-sheets annotated in blue and alpha helices in pink. 
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Figure 2.2: HHPred alignment of B3 to Flp. 
Results from B3 HHPred alignment to Flp recombinase (PDB: 1FLO, chain A) are reproduced here 
with additional annotations indicating split locations, catalytic residues, and secondary structure 
names adapted from a literature source[141]. Three-dimensional structure of Flp recombinase is 
plotted with beta-sheets annotated in blue and alpha helices in pink. 
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Figure 2.3: Cloning strategy for building split recombinases. 
(a) A schematic showing the process for cloning split recombinase fragments into CID backbones.  (b) 
Series of vectors containing CID and LID domains. NLS indicates the SV40 nuclear localization 
sequence. 
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Figure 2.4: Screens of split locations yield small-molecule dependent recombination responses.  
Cre, Flp, VCre, B3, ɸC31, and TP901 recombinases (a through f) were split into two fragments at 
amino acid S and fused to gibberellin-inducible (GAI/GID1) or rapalog (FKBP/FRB) 
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heterodimerization domains. Splits were made at various amino acid locations; pink, blue and gray 
shaded regions indicate alpha helices, beta sheets, or undetermined structures, respectively. Split 
recombinases were transfected along with reporters that yield green fluorescence protein (GFP) 
expression upon site-specific recombination (g through l). Constitutive recombinases (black square) or 
a blank vector (gray squares) were transfected to indicate highest or lowest expected GFP expression. 
Split recombinases were also transfected, and drug was either added (green squares) or not added 
(white squares) was added to the cell culture medium after two hours. M.F.I. indicates mean 
fluorescence intensity measured with arbitrary units (a.u.). Errors bars represent standard error of the 
mean of three transfected cell cultures. 
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Figure 2.5: Screen of two locations in Bxb1 integrase. 
(a) Bxb1 was split into two fragments at amino acid S and fused to gibberellin-inducible (GAI/GID1) 
heterodimerization domains. Splits were made at two amino acid locations; pink, blue and gray shaded 
regions indicate alpha helices, beta sheets, or undetermined structures, respectively. Split 
recombinases were transfected along with reporters that yield green fluorescence protein (GFP) 
expression upon site-specific recombination (b). Constitutive Bxb1 (black square) or a blank vector 
(gray square) were transfected to indicate highest or lowest expected GFP expression. Split 
recombinases were also transfected and drug (green squares) or no drug (white squares) was added to 
the cell culture medium after two hours. M.F.I. indicates mean fluorescence intensity measured with 
arbitrary units (a.u.). Errors bars represent standard error of the mean of three transfected cell cultures. 
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Figure 2.6: Comparison of original split Cre (diCre) with newly developed split Cre 
recombinases. 
(a and b) Cre was split into two fragments at amino acid S and fused to gibberellin-inducible 
(GAI/GID1) heterodimerization domains at various termini. Split recombinases were transfected along 
with reporters that yield green fluorescence protein (GFP) expression upon site-specific recombination 
(c). Constitutive Cre (black square) or a blank vector (gray square) were transfected to indicate highest 
or lowest expected GFP expression. Split recombinases were also transfected and drug (green squares) 
or no drug (white squares) was added to the cell culture medium after two hours. M.F.I. indicates 
mean fluorescence intensity measured with molecules of equivalent fluorescein (MEFL). Error bars of 
M.F.I. indicate the standard deviation between three transfected cell cultures. 
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Figure 2.7: Swapping chemical-inducible dimerization domains yield a large repertoire of small-
molecule inducible recombinases.  
(a) A Signal-to-Noise (SNR) metric can be used to capture both the absolute difference in mean signal 
expression and spread (“noise”) of the distributions. SNR dynamics in units of decibels (dB) were 
captured over 100 hours post-transfection for particular amino acid splits of inducible Cre (b), Flp (c) 
and ɸC31 (d) systems incorporating the gibberellin (GIB), rapalog (RAP) and abscisic acid (ABA) 
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dimerization domains GAI/GID1, FKBP/FRB and PYL/ABI, respectively. A 4-hydroxytamoxifen 
(4OHT)-inducible pCAG-ERT2-Cre-ERT2 construct is included in (b). Various splits of Cre (e and f) 
Flp (g and h), VCre (i and j) and ɸC31 (k and l) were incorporated with the GIB, RAP and ABA-
associated dimerization domains. Measurements of GFP mean fluorescence intensity (M.F.I.) in units 
of molecules of equivalent fluorescein (MEFL) and SNR were made for plus drug (colored blue, 
purple, and pink squares corresponding to gibberellin, rapalog, and abscisic acid) and minus drug 
(white squares) conditions. Constitutive recombinases (black squares) and blank vectors (gray 
squares) were also transfected as a comparison. Red diamonds indicate SNR score. Error bars of 
M.F.I. indicate the standard deviation between three transfected cell cultures. 
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Figure 2.8: Comparison of domain orientations with four splits of Flp recombinase. 
(a) Flp was split into two fragments at amino acid S and fused to gibberellin-inducible (GAI/GID1), 
rapalog-inducible (FKBP/FRB) or abscisic acid-inducible (PYL/ABI) dimerization domains. Split 
recombinases were transfected along with reporters that yield green fluorescence protein (GFP) 
expression upon site-specific recombination (b). Constitutive Flp (black square) or a blank vector 
(gray square) were transfected to indicate highest or lowest expected GFP expression. Split 
recombinases were also transfected and drug (green squares) or no drug (white squares) was added to 
the cell culture medium after two hours. Depictions of domains indicated the orientation of the 
domains with respect to the schematic in (a). M.F.I. indicates mean fluorescence intensity measured 
with arbitrary units (a.u.). Errors bars represent standard error of the mean of three transfected cell 
cultures. 
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Figure 2.9: Light and temperature-inducible recombinases. 
(a) A schematic showing a split Cre fused to nMag and pMag blue light-inducible dimerization 
domains. (b) Pulses indicating the changing light (left) and temperature (center and right) conditions. 
Plots indicate GFP mean fluorescence intensity (M.F.I.) of various nMag/pMag tagged split Cre (c) 
and Flp (d) recombinases under blue light (blue squares), room temperature (pink squares) and 
refrigerated (purple squares). Black squares indicate samples treated with constant temperature and 
dark conditions. PA-Cre indicates expression of a previously developed blue-light inducible Cre 
recombinase[131]. Inducible recombinases were compared with samples transfected with constitutive 
recombinases or a blank vector. Error bars of M.F.I. indicate the standard error of the mean between 
three transfected cell cultures. 
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Figure 2.10: Protein and DNA-based recombinase logic gates. 
(a) A two-input protein-based AND-gate is created by splitting Flp recombinase at two locations (S1 = 
27, S2 = 396) and fused to the gibberellin (GIB) and abscisic acid (ABA)-associated chemical 
inducible dimerization domains. (b) Plotted results indicate GFP mean fluorescence intensity (M.F.I.) 
of four conditions of GIB and ABA. (c) Four chemical inducible recombinases can be used together to 
generate a DNA-based 4-input logic gate; these include a gibberellin-inducible split Bxb1 (S = 468), 
4-hydroxytamoxifen (4OHT)-inducible ERT2-Cre-ERT2, abscisic acid (ABA)-inducible split Flp (S = 
396), and rapalog (RAP)-inducible split ɸC31 (S = 571). (d) Plotted results indicate GFP M.F.I. of 
sixteen conditions of GIB, 4OHT, ABA and RAP. Error bars of M.F.I. indicate the standard error of 
the mean between three transfected cell cultures. 
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Figure 2.11: An alternative pick of two splits does in Flp recombinase does not yield a functional 
2-input protein-based AND gate. 
(a) A two-input protein-based AND-gate is created by splitting Flp recombinase at two locations (S1 = 
27, S2 = 396) and fused to the gibberellin (GIB) and abscisic acid (ABA)-associated chemical 
inducible dimerization domains. (b) Plotted results indicate GFP mean fluorescence intensity (M.F.I.) 
of four conditions of GIB and ABA. (c) Four chemical inducible recombinases can be used together to 
generate a DNA-based 4-input logic gate; these include a gibberellin-inducible split Bxb1 (S = 468), 
4-hydroxytamoxifen (4OHT)-inducible ERT2-Cre-ERT2, abscisic acid (ABA)-inducible split Flp (S = 
396), and rapalog (RAP)-inducible split ɸC31 (S = 571). (d) Plotted results indicate GFP M.F.I. of 
sixteen conditions of GIB, 4OHT, ABA and RAP. Error bars of M.F.I. indicate the standard error of 
the mean between three transfected cell cultures. 	
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CHAPTER THREE: Boolean Logic and Arithmetic through DNA Excision  
3.1 Introduction 
A fundamental goal of synthetic biology is to predictably and efficiently 
reprogram cells to perform computations and carry out specific biological tasks [142]. 
Cells genetically engineered with biocomputation circuits hold great promise for 
improving therapeutics [7, 26, 143, 144], diagnostics [22, 145], animal models [40, 41] 
and industrial biotechnological processes [11, 146]. Despite rapid advances and 
promising results in biocomputation design [38, 147-150], implementing simple two-
input, single-output Boolean functions in prokaryotic and eukaryotic cells necessitated 
layering of multiple genetic circuits, requiring extensive construction and tuning of 
genetic components. Circuits with multiple inputs and multiple outputs remain scarce in 
scientific literature due to the need of a large library of interoperable genetic parts and the 
compounding effects of connecting increasingly more transcriptional components 
together into single cells [151]. Curation of genetic circuit components and the 
development of automated design software are starting to address these problems in 
bacteria [152-156], but are not currently available for mammalian cells. It is not clear 
whether either parts or design software can be transferred from bacteria to higher 
organisms. 
To enable complex computation in mammalian cells, we present a 
biocomputation platform named Boolean Logic and Arithmetic through DNA Excision 
(BLADE) that can be used to create decision-making circuits using site-specific 
recombinase technology. To our knowledge, BLADE provides the first generalizable 
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framework for engineering complex logic functions in mammalian cells with minimal 
optimization by the user. Unlike most circuit designs already published, our platform 
encodes genetic logic through a single-layer design, which can readily yield circuits with 
multiple inputs or outputs without increasing the number of transcription units.  
We use our platform to design, build, and test more than 100 functionally distinct 
circuits, including some of the most complex logical operations engineered in any living 
cell to date. Our platform accommodates multiple outputs without incurring additional 
design complexity and can be adapted to regulate the expression of messenger RNAs 
from Pol II promoters or non-coding regulatory RNAs from Pol III promoters, such as 
CRISPR/Cas9 guide RNAs. Being able to build complex logic circuits that control 
multiple different guide RNAs could enable exquisite control of endogenous mammalian 
gene expression. 
3.2 Results 
3.2.1 Characterization of Recombinases 
Site-specific DNA recombinases, which are a class of DNA-modifying enzymes 
that recognize a specific DNA sequence and perform cleavage and reunion of DNA [32], 
show promise for use in building synthetic circuits in eukaryotic cells. This is in part due 
to their versatile ability to simultaneously function as transcriptional activators and 
repressors within the same cell on the same transcription unit; a feat that is difficult to 
achieve with transcription factors. Recombinase-mediated gene expression can be 
achieved by tyrosine recombinase-mediated excision of a transcription terminator located 
upstream of a gene of interest (GOI) or serine integrase-mediated inversion of a GOI 
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(analogous to a buffer BUF gate) (Figure 3.1a). Conversely, termination of gene 
expression can be achieved by the placement of recombination sites around a GOI and 
elimination of gene expression using tyrosine recombinase-mediated excision or serine 
integrase inversion (analogous to a NOT gate). 
 Multi-input recombinase-based biological computational circuits require robust 
and orthogonal genetic components. Here, twelve recombinases, including both tyrosine 
recombinase and serine integrase families were tested for activity and orthogonality in a 
human embryonic kidney cell line (HEK293FT). Through transient transfection of 
recombinases and their reporters (deletion-based BUF gates for tyrosine recombinases 
and inversion-based for serine integrases), ten of the enzymes were found to be highly 
active and sufficiently orthogonal to each other for our circuit design effort (Figure 3.1b, 
Figure 3.2a, Table 3.1). It was found that recombinase expressional level could be tuned 
to minimize cross-talk between non-orthogonal recombinases (Figure 3.3). We focused 
our efforts on the use of Cre and Flp recombinases due to their extensive prevalence in 
mammalian cell culture and animal experimentation. 
Through an ad-hoc design approach, we created all sixteen possible two-input 
Boolean logic gates by placing Cre and Flp recombination sites (loxP and FRT, 
respectively) around termination and coding sequences to yield the intended behaviors 
(Figure 3.4, Table 3.2). Due to the orthogonality of recombinases, it is possible to 
generate multi-input AND gates simply by placing more termination sequences in tandem 
between a promoter and GFP. Indeed, we created a 6-input AND gate that expresses GFP 
upon the excision of four termination sequences by tyrosine recombinases and the 
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inversion of the EF1α promoter and GFP by two serine integrases (Figure 3.1c, Figure 
3.2b, Table 3.3). 
A key element that is required to implement more complex functions on a single 
transcriptional unit is the use of heterospecific recombination sites. Heterospecific sites, 
such as loxP and lox2272, differ from one another by only a few base pairs [157], but 
they retain DNA excision capabilities in the presence of Cre, as long as two of the same 
sites are present, i.e. loxP with loxP. We validated three sets of lox sites (loxP, lox2272, 
loxN), three sets of FRT (FRT, F3, F14) and Vlox (VloxP, Vlox2272), which 
demonstrated heterospecificity using Cre, Flp, and VCre enzymes, respectively (Figure 
3.5, Table 3.4). This feature allows the excision of more than one non-connected region 
of DNA simultaneously, enabling encoding of logic on a single-layer (recombinase inputs 
recombining with a single DNA strand reporter). This is juxtaposed to transcription-
factor based genetic logic, which necessitates cascading connections of multiple 
transcriptional responses; here, extensive fine-tuning is usually required to engineer 
functional circuits to balance input-output responses, which grows substantially as the 
number of inputs and outputs of the circuits increases. 
3.2.2 Single-layer Multi-Input Recombinase-based Design Platform 
Although an ad hoc design approach can be successful in creating some 
recombinase-based circuits as we have demonstrated here and others have in scientific 
literature,[18, 19, 40, 41, 45] a generalizable strategy for producing any N-input-M-
output logic behavior has not, to our knowledge, been demonstrated before. We exploited 
the features of site-specific recombinases to establish a platform for N-input-M-output 
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combinatorial computation in mammalian cells named Boolean Logic and Arithmetic 
through DNA Excision (BLADE), where N and M can be any non-negative integer. 
Beyond the orthogonality of the recombinases and heterospecific sites, no further 
characterization of individual components is needed. 
Each BLADE circuit is organized as a single transcriptional layer comprising a 
single promoter upstream of up to 2N regions of DNA sequences (or addresses, Z), which 
are surrounded by recombination sites. Each BLADE circuit is designed such that when it 
is presented with recombinase inputs, addresses become transcriptionally active through 
excision of intervening regions between recombination sites downstream of the promoter. 
For example, a two-input (N = 2) BLADE circuit, which responds to inputs A and B, can 
accommodate up to 22 = 4 addresses with possible addresses being Z = ZAB = Z00, Z10, 
Z01, and Z11, enumerating all combinatorial states of inputs A and B (Figure 3.6a). The 
BLADE design is flexible with regards to the outputs that can be generated. Outputs can 
range from no transcriptional outputs (transcription terminator) at all, an arbitrary 
combination of outputs separated by ribosomal skip sequences (2A), Boolean functions 
like BUF that can toggle transcriptional responses ON or OFF through use of additional 
site-specific recombinases, or even other BLADE topologies. A BLADE design that 
utilizes 2N addresses permits creation of all possible N-input-M-output combinatorial 
circuits and thus is necessary for implementing the most complex multi-input-multi-
output truth tables [158]. 
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3.2.3 A Two-Input, Four-Output Circuit 
For initial characterization of the 2-input BLADE platform, single transcriptional 
output functions were tested. We constructed a 2-input, 4-output decoder circuit, which 
necessitates four addresses, each of which coincides with a distinct output: blue, green, 
infrared and red fluorescent proteins (tagBFP, EGFP, iRFP720, and mRuby2, 
respectively) using a modular assembly strategy known as Unique Nucleotide Sequence-
Guided Assembly, based on Gibson isothermal assembly [159, 160] (Figure 3.6b, 
Figures 3.7-3.11). One advantage of the BLADE platform is that expression of outputs is 
driven by a single promoter, thereby permitting additional control through the use of a 
drug-regulated promoter or encoding of further transcriptional logic. We demonstrated 
this principle by stable integration of a doxycycline-controlled decoder circuit into Jurkat 
T lymphocytes using piggyBac-mediated transposition. Jurkat T cells were chosen 
because they are an important suspension cell line for understanding T cell signaling and 
easy to maintain during long-term passages. Constitutively-expressing recombinases 
were then integrated into the genome. Following stable integration of the recombinases 
driven by constitutive promoters, doxycycline was used to regulate final output 
expression in a dose-dependent manner (Figure 3.12). This strategy provides a facile way 
of scaling the circuit response while maintaining the logical functionality of the circuit. 
Furthermore, we showed that BLADE circuit functionality can be maintained for at least 
two weeks under varying doxycycline conditions (Figure 3.13). Moreover, the decoder 
circuit performed as predicted through transient transfection of HEK293FT cells with 
strong fluorescent protein expression for each state of inputs (Figure 3.14, Table 3.5). 
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HEK293FT was chosen here (and for subsequent experiments) because high throughput 
experimentation is enabled due to the inexpensive and highly efficient polyethylenimine 
transfection reagent. 
3.2.4 Scaling Up and Quantitation of Circuit Design 
To test the robustness of the BLADE platform on a large scale, we produced the 
largest collection of functionally unique logic circuits in mammalian cells (a library of 
113 circuits with up to two inputs and outputs (Figure 3.15 and Figure 3.16). This set 
contains two 2-input circuits: the half adder (Gate 104) and half subtractor (Gate 99), 
which perform 2-input arithmetic and are widely-used and studied in electronics. 
Whereas all 113 circuits were qualitatively observed to implement the correct 
computation, we quantified their functional correctness using a novel Vector Proximity 
(VP) metric measuring the misalignment between a circuit’s biological implementation 
and its ideal implementation from its intended truth table. Truth tables and obtained 
experimental results were represented as vectors, Truth Table and Signal Vectors, 
respectively, in an 8-dimensional vector space. The angular error between these two 
vectors (VP angle metric) was calculated with 0° meaning the data represents the 
intended truth table perfectly and 90° meaning the data demonstrates completely 
incorrect output (inverted response to the intended truth table). The VP angle metric 
shows that 93.8% (106/113) of the circuits had an angle no more than 15°, and none had 
an angle of more than 25° from their ideal implementation. 
We extended the VP measure of correctness to obtain a quantitative and discrete 
test of whether an implemented circuit is correct or incorrect. For any implemented 
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circuit we measured its VP angle from all possible truth tables, and sorted the results in 
ascending order. We define the rank of the intended truth table in this sorted list as the 
circuit’s VP global rank. We call a circuit as functionally valid under this measure, if it 
has the best (that is, smallest) VP global rank. For our library of 113 circuits, we 
calculated the VP angle between each Signal Vector and all 255 (up to 2-input, up to 2-
output, excluding the 0-input, 0-output FALSE) Truth Table vectors. Global rank values 
were determined according to how many Truth Table Vectors had lower VP angles than 
the Intended Truth Table Vector. We found that 96.5% (109/113) of the tested circuits 
gave the lowest angle between their Signal Vector (global rank = 0/255) and their 
Intended Truth Table vectors (Figure 3.17 and Table 3.6). This success rate of 96.5% is 
the highest reported to our knowledge for large scale circuit construction in mammalian 
cells. Only four circuits had a global rank of 1, meaning there was only one other truth 
table that yielded a lower VP angle; no circuits had a rank more than 1. To facilitate data 
sharing and further analysis by other researchers, we have developed an interactive 
website (datasheets.synbiotools.org) that contains the data all of our 113 circuits 
summarized in a datasheet format [161]. 
3.2.5 Re-Programmable Combinatorial Logic 
One important class of circuits found in electronics is Field-Programmable Read-
Only Memory (FPROM). The input-output behavior of these circuits can be configured 
in the field post-manufacturing, allowing users to program the function computed by the 
circuit at a later time. We built a genetic FPROM circuit for living cells termed a Boolean 
Logic Look-Up Table (LUT) that is based on placing BUF gates into the four addresses 
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of the 2-input BLADE template. (Figure 3.18, Figure 3.19, Table 3.7). This circuit has 
two data inputs, A and B, and four select inputs, S1, S2, S3, and S4. Each select input can 
control which buffer gates are transcriptionally active or not (GFP ON or OFF). Thus, 
each combination of select inputs configures the circuit to one of sixteen-possible 
Boolean logic gates with up to two inputs and one output. For instance, an OR function 
can be achieved using select inputs S2, S3, and S4, keeping address Z00 GFP OFF and 
setting addresses Z10, Z01, and Z11 GFP ON. Thus, this circuit allows one to reconfigure 
the computation within living cells without requiring additional DNA assembly. This 
circuit behaves as expected in HEK293FT cells. To illustrate the flexibility of our 
platform in terms of recombinase choices, we created an alternative Boolean Logic LUT 
(Figure 3.20).  
3.2.6 Arithmetic Operations Using BLADE 
Extending the BLADE framework further, we developed a 3-input BLADE 
template for constructing sophisticated arithmetic functions in human cells (Figure 
3.21a, 3.22 and 3.23). This template responds to three inputs (Cre, Flp, and VCre) and 
contains eight addresses for expression of up to eight distinct transcriptional outputs. This 
design utilizes three different heterospecific sites for Cre and Flp, but just one site for 
VCre. Three 3-input-2-ouput arithmetic computational circuits were made and tested in 
HEK293FT cells from the 3-input BLADE template (Figure 3.21b, Figure 3.24, Table 
3.8). The full adder and full subtractor can perform either binary addition or subtraction 
of three 1-bit inputs, respectively. Furthermore, the half adder-subtractor is an arithmetic 
FPROM circuit that can compute addition or subtraction on two data inputs, A and B, 
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depending on the presence of one select input C. BLADE templates with more than three 
inputs can be generated by using additional recombinases and heterospecific 
recombination sites that follow a simple recursive design algorithm where recombinase 
switches are nested within each other yielding designs for implementing any N-input 
combinatorial logic function (Figure 3.25). This non-intensive computational approach 
produces designs with the total number of recombination site pairs for N-inputs being 2N-
1, for N≥0; this is consistent with the 2N rows needed to specify the truth table of an N-
input function. 
3.2.7 Small Molecule Inputs for BLADE 
Next, we interfaced the BLADE system with biochemically relevant inputs. To 
induce Cre recombination, an ERT2-Cre-ERT2 construct was used whereby a mutated 
estrogen receptor (ERT2) secludes Cre recombinase activity from the nucleus unless a 
small molecule 4-hydroxytamoxifen (4OHT) is added, which permits translocation of the 
fusion protein to the nucleus. For Flp induction, a split Flp system was developed that 
induces Flp recombinase activity upon phytohormone abscisic acid (ABA)-induced 
heterodimerization (Figure 3.26a, Figure 3.27, Table 3.9). Logical detection of these 
two small molecule inputs was successful using the 2-input BLADE decoder with 
minimal leaky recombinase behavior in HEK293FT cells. Logic induction dynamics 
were characterized over the course of 48 hours, which revealed early encoding of logic 
and introduction of leaky recombinase behavior towards the end of the time course 
(Figures 3.28, 3.29 and 3.30). A BLADE decoder affords the ability to combinatorially 
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select an exponential number of DNA regions (e.g. eight regions via three inputs), which 
is advantageous for the limited set of eukaryotic inducible systems. 
3.2.8 CRISPR/Cas9 Combined with BLADE 
To test whether the BLADE system can be used to regulate endogenous 
mammalian gene expression, we interfaced it with the CRISPR/Cas9 system using 
recombinase-based excision of guide RNA (gRNA) sequences. We first tested whether 
recombination sites or cloning scar DNA sequences would affect the activity of a Cas9 
transcription activator (dCas9-VPR), as these sequences would be directly coded into 
RNA fused to the gRNA. We found that these sequences (up to 136 bases) added to the 
5’ end of the gRNA had no detrimental effect on transcription activation of a mCherry 
reporter plasmid (Figure 3.31). Next, the two-input decoder was rebuilt to use an RNA 
polymerase III human U6 promoter and single guide RNAs (gRNAs) as addresses that 
target promoters of four human endogenous genes (NGN2, MIAT, ACTC1 and TTN). 
These targets were chosen because of their documented efficient gRNA activity [60]. 
This CRISPR-based two-input decoder system was transfected along with a Cas9 
transcription activator (dCas9-VPR) [60] and recombinase activities were induced with 
4OHT and ABA (Figure 3.26b, Tables 3.10 and 3.11). At the completion of the 
HEK293FT transient transfection, mRNA fold changes of the target endogenous genes 
were determined using quantitative real-time PCR and corresponded to the two-input 
decoder truth table logic. Owing to the easy programmability of the CRISPR/Cas9 
system, this system will be very useful for genome-wide transcriptional reprogramming 
studies, entailing unprecedented control of endogenous human genes and cell states. 
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3.3 Discussion 
Composition of simple gates into large hierarchies of modules has been successful 
in electronic circuit design because components are physically separated from each other, 
allowing reuse of well-characterized and high-performing parts. This has enabled 
computing circuits with extremely predictable behaviors to be built. However, applying 
this electrical engineering strategy to synthetic biology has proven difficult due to the 
lack of a complete understanding of how different components will behave when 
connected together in a single cell [151, 162], even when these components were 
designed to be “plug and play”. As such, aside from some elegant work[117, 148], very 
few synthetic multi-input-multi-output circuits have been reported. Furthermore, this 
multi-layer circuit design approach also requires many orthogonal biological “wires” 
which have unpredictable properties. This has driven effort toward parts development 
[163, 164] at the expense of circuit design. Efforts are underway to provide detailed 
characterization of components and develop standards and design automation program to 
allow for better predictability of the interoperability of different parts [152, 161].  
The BLADE platform is enabled by the unique chemistry of recombinases (DNA 
rearrangement) in regulating gene expression. The same recombinase can activate and 
inhibit gene expression simultaneously in the same transcription unit with equal 
efficiency, a feature that is very difficult to accomplish with transcription factors. This 
feature allowed us to design the BLADE platform in a single-layer (single transcription 
unit) to implement any combinatorial Boolean logic provided sufficient numbers of 
recombinases and heterospecific sites are available. We define the number of layers in a 
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computing circuit as the maximum number of states along the shortest path in any 
computation. By "single-layer," we connote the following property unique to BLADE 
designs. Unlike other circuit architectures, there is no distinct "molecular wire" needed to 
communicate the results of a sub-computation in one part of the circuit to any other part 
of the circuit: the inputs themselves communicate information throughout a computation. 
Our single-layer BLADE platform can also use fewer protein components to perform a 
large set of complex logical operations in mammalian cells. Single-layer circuits do not 
need output signal levels of one gate to be tuned or matched to input signal levels of 
another. A trade-off of a single-layer design is that the performance of circuits cannot be 
predicted based on the property of its components.  
Some circuits did not pass our stringent VP global rank metric evaluation; 
however, all circuits yielded results that had close alignment with their intended truth 
table. A potential source of underperformance could arise from interference of 
recombinase sites sequences on ribosome activities (e.g. hair-pinning hampering 
translation initiation or cryptic translation initiation sequences). The RNA Pol 
III/CRISPR-based BLADE system could be an attractive circuit design to explore since 
gRNA or other regulatory RNA outputs are not subjected to translation-based failure 
modes.  
Transcription factor-based genetic circuits have played a substantial role in 
synthetic circuit design [9, 25, 115, 152]. This is because natural genetic circuits, which 
commonly serve as the inspiration for synthetic circuit design, are mostly implemented 
using transcription factors, with only a few documented cases involving recombinases 
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(e.g. fim invertase in Escherichia coli) [165, 166]. Unlike transcription-based circuits, 
recombinase-based circuits are single-use systems, which prevent them from tracking 
dynamic input signals. However, recombinases are particularly advantageous for 
engineering logic behaviors. Furthermore, when integrated into the genome, 
recombinase-based systems can provide stable memory and have proven to be invaluable 
in numerous experiments, such as in tissue specific gene expression experiments where 
memory of tissue or condition specific inputs that lead to sustained gene expression (or 
knockout) is more desirable. In addition, serine integrases have been used to develop 
temporal logic state machines in bacteria where the circuits can sense and remember the 
order in which signal inputs appeared [122, 167]. It is conceivable that those designs can 
be refactored to function in mammalian cells. It is also possible to modify the BLADE 
platform to perform temporal logic computations, thus enabling the use of the more 
widely adopted tyrosine recombinases in a single-layer circuit topology. The prevalence 
of recombinases in different systems and organisms illustrates the fact that single-use 
systems are often sufficient in biomedical research and biotechnological applications [32, 
168].  
Genome-mining has been performed to uncover and test a large set of serine 
integrases [15] and many putative recombinases remain to be characterized from 
structural identification in genome sequence databases. Furthermore, efforts have been 
made to design and implement recombinases that can be made to recombine different 
DNA sequences through fusion of recombinase catalytic domains to programmable 
DNA-binding proteins, such as zinc finger, TAL, and Cas9 sequences [169-171]; 
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generation of chimeric recombinases [172]; or alteration of specificity through molecular 
evolution experiments [173]. Therefore, we envision that an unlimited set of recombinase 
parts are likely available for incorporation with BLADE to create biocomputation circuits 
with unprecedented sophistication.  
3.4 Conclusion 
The BLADE platform that we present here can generate a large number of 
complex genetic circuits. To demonstrate the application of BLADE in genetic circuit 
design, we created more than 100 functionally distinct circuits, most of which have never, 
to our knowledge, been documented before in any living organism. Most of the circuits 
that we built displayed the intended logic, as quantified by the VP metrics that we 
devised to quantitate performance. BLADE can be used to regulate messenger and guide 
RNA expression, thus increasing flexibility in the modulation of cell functions. When 
combined with drug-inducible control of recombinase activity, we were able to 
conditionally regulate gene expression and cell states. We created a split Flp protein 
whose activity can be reconstituted with chemically inducible dimerization systems. This 
split Flp configuration could be valuable to animal geneticists to complement existing 
Cre systems. Furthermore, we have shown that the BLADE system is functional in 
different cell types (e.g. embryonic kidney and Jurkat T cells). Key attributes of the 
BLADE platform are summarized in Table 3.12. 
		
92 
3.5 Methods 
3.5.1 DNA Assembly 
All constructs were transformed and maintained in Top10 Escherichia coli 
competent cells (Life Technologies) at 37°C or 30°C prior to miniprep (Epoch Life 
Sciences) or midiprep (Macherey Nagel). All plasmids were created using standard 
molecular biology practices of ligation, digestion and transformation, in addition to 
Gibson isothermal assembly and Unique Nucleotide Sequence Guided assembly (a 
modular extension of Gibson assembly), where DNA fragments that are to be connected 
to each other are flanked by short homology sequences and are then fused together by a 
one-pot isothermal digestion, polymerization, and ligation reaction. This latter strategy 
permits a modular, easy, efficient and fast framework for construction of DNA. In UNS-
guided assembly, the homology sequences have been standardized (e.g. U1, U2, 
U3…UX) and have been computationally optimized for proper assembly (reduction of 
hairpins, sequence homology, and GC tracts) and ease of use (no start codons or useful 
restriction sites). Genetic cassettes that are to be connected are cloned into part vectors, 
which contain the UNSes that surround the insert. Part vectors are then sequenced-
verified using Sanger sequencing (Quintara Biosciences). Restriction digests and gel 
purifications are then performed to isolate the cassettes flanked with the UNSes. Finally, 
these products are joined to a linearized destination vector via Gibson isothermal 
assembly. For the 113 circuits displayed in Figure 3.15, analytical PCRs were performed 
to verify inserts were assembled correctly through amplifications across the UNS 
sequences. 
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3.5.2 Maintenance and Transient DNA Transfection of HEK293FT cells 
DNA was transfected into the human embryonic kidney cell line (HEK293FT) 
using a polyethylenimine (PEI) protocol. Cells were plated onto 48- (250µL) or 96-well 
(100µL) plates the day prior to transfection (200,000 cells/mL), such that the cells were 
50-70% confluent the day of transfection. Cells were kept in a humidified incubator at 
37°C and 5%CO2 and maintained in DMEM medium (Corning) with 10% Heat 
Inactivated Fetal Bovine Serum (Life Technologies), 50U.I./mL penicillin/ 50µg/mL 
streptomycin (Corning), 2mM glutamine (Corning) and 1mM sodium pyruvate (Lonza). 
PEI stocks were made from linear polyethylenimine (Polysciences 23966-2) and were 
dissolved at a concentration of 0.323g/L in deionized water with the assistance of 
concentrated hydrochloric acid and sodium hydroxide and then filtered sterilized 
(0.22µm). PEI stocks were stored at -80°C until use and warmed to room temperature 
prior to usage. For 48-well plate transfections, DNA (1000ng, 50ng/µL) was dissolved 
and brought up to a volume of 50µL using 0.15 M sodium chloride (NaCl, Fisher 
Scientific). DNA-NaCl solutions were then mixed with 50µL of a PEI-NaCl mixture 
(8uL PEI: 42uL NaCl). These solutions were then incubated at room temperature for ten 
minutes and 25µL was carefully dropped into individual wells of HEK293FT cells 
(250ng DNA/well). Similarly, for 96-well plate transfections, DNA (500ng, 50ng/µL) 
was dissolved and brought up to a volume of 25µL using 0.15 M sodium chloride (NaCl). 
DNA-NaCl solutions were then mixed with 25µL of a PEI-NaCl (4uL PEI: 21uL NaCl) 
mixture. These solutions were then incubated at room temperature for ten minutes and 
10µL was carefully dropped into individual wells of HEK293FT cells (100ng 
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DNA/well). Electronic space-adjustable multichannel pipettors (Integra Biosciences) 
were utilized throughout the process for rapid aspiration and dispensing of molecular and 
cellular reagents. A Countess II image-based cell counter (Life Technologies) was used 
for measuring human cell population densities. 
3.5.3 Small molecule chemical induction 
1000X stock small molecules abscisic acid (100mM, Sigma Aldrich), doxycycline 
(200µg/mL, Fisher Scientific), and 4-hydroxytamoxifen (1mM, Sigma Aldrich) were 
dissolved in 100% ethanol and stored at recommended temperatures. For transient 
transfection induction experiments, two hours post-transfection, small molecules were 
mixed with mammalian cell medium such the concentrations were 25X; then, proper 
volumes were dispensed into wells such that the final concentration was 1X.  
3.5.4 Maintenance and Generation of Stable Jurkat T Lymphocytes Through 
Electroporation, PiggyBac-mediated Integration, Eukaryotic Selection, and Doxycycline 
Induction 
Wild type Jurkat T lymphocyte cells were kept in a humidified incubator at 37°C 
and 5%CO2 and maintained in RPMI medium (Corning) with 5% Heat Inactivated Fetal 
Bovine Serum (HI-FBS, Life Technologies), 50U.I./mL penicillin/ 50µg/mL 
streptomycin (Corning), and 2mM glutamine (Corning). Prior to electroporation, cells 
were changed with medium containing 10% HI-FBS and without antibiotics. On days of 
transfection, cells were checked to be within 5-8x105 cells/mL and 2x107 cells were spun 
down at 300xg and resuspended in 300µL medium per transfection. Cell solutions were 
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mixed with 20µg transposon vector and 4µg of transposase (pCAG-SuperPBase, 
pBW900). After fifteen minutes of room temperature incubation, DNA/cell mixtures 
were transferred to a 4mm electroporation cuvette and electroporated in a Harvard 
Apparatus BTX instrument using a single pulse 300V square wave for ten milliseconds. 
Cells were then transferred to 10% HI-FBS medium without antibiotics and placed into 
the incubator. One to two days later, cells were spun down and resuspended in medium 
with 5% HI-FBS with antibiotic and antieukaryotic chemicals. Puromycin (Thermo 
Scientific) was used at a final concentration of 2µg/mL and zeocin (Invivogen) at 
400µg/mL. Antieukaryotic selections were performed for at least ten days before 
removing antieukaryotic compounds. 
For experiment in Figure 3.6b, the decoder recombinase reporter (pBW2293) was 
first integrated and selected with zeocin; then, recombinase expression vectors (hPGK-
iCre, hPGK-FlpO, hPGK-FlpO-2A-iCre) were integrated and selected for with 
puromycin in duplicate (n=2). After final stable line generation, 300,000 Jurkat cells of 
each line were spun down and resuspended in doxycycline or ethanol-containing 
medium. Cells were maintained in respective media for given number of time (fourteen 
days in ethanol and then with or without doxycycline for three days in Figure 3.6b, 
square points in Figure 3.13) and then run for cytometric readings.  
3.5.5 Flow Cytometry 
Two days post-transfection and after trypsinization (0.05%Trypsin/0.53mM 
EDTA, Corning) and resuspension, all HEK293FT cell populations were analysed using 
a Becton Dickinson (BD) LSRFortessa SORP flow cytometer with HTS, except for data 
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in Figure 3.21, which were recorded on a BD LSRII. Time-course data was achieved 
through trypsinization and fixation of cells at particular time points (BD Cytofix) and 
kept at 4°C until analysed through flow cytometry. The LSRFortessa was equipped for 
detection of EGFP (488nm laser, 530/30 emission filter, 505 longpass dichroic mirror), 
tagBFP (405nm laser, 450/50 emission filter), mCherry or mRuby2 (561nm, 610/20 
emission filter, 595 longpass dichroic mirror), iRFP-720 (637nm laser, 730/45 emission 
filter, 685 longpass dichroic mirror) and LSS-mOrange (405nm, 610/20 emission filter, 
535 longpass dichroic mirror). The LSRII was similarly equipped for detection of EGFP, 
tagBFP, mCherry and mRuby2, but with additional channels for iRFP-720 (633nm laser, 
720/40 emission filter, 710 longpass dichroic mirror) and LSS-mOrange (405nm, 590/35 
emission filter, 505 longpass dichroic mirror). All Jurkat T lymphocyte experiments were 
run using a Life Technologies Attune Nxt 4-laser acoustic focusing flow cytometer. The 
Attune Nxt was equipped for detection of EGFP (488nm laser, 510/10 emission filter), 
tagBFP (405nm laser, 440/50 emission filter), mRuby2 (561nm, 585/16 emission filter), 
iRFP-720 (638nm laser, 720/30 emission filter) and LSS-mOrange (405nm, 603/48 
emission filter). 
A gate was applied on FSC-A and SSC-A to remove debris from cell populations 
in FlowJo (Tree Star) (Figure 3.32). pCAG-tagBFP or pCAG-LSS-mOrange plasmids 
were used as HEK293FT transient transfection markers and were gated for by applying a 
gate on the top 0-0.1% wildtype cells in those channels. Figure plots represent at least 
5000 events in the transfected cell subset. Compensation was applied for four and five-
color experiments (Figure 3.33, Figure 3.34, and Figure 3.35). No gates other than a 
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viable cell FSC/SSC were applied for Jurkat T lymphocyte stable line experiments. To 
demonstrate the digital ON/OFF behavior of the genetic circuits, main text plots have 
additionally been expressed as percentage of cells in an ON state through application of 
gates in fluorescent protein channels. Gates were chosen per experiment in an arbitrarily-
defined manner, but applied uniformly for all samples in each experiment. 
3.5.6 Quantitative Real-Time Polymerase Chain Reaction Analysis 
RNA was extracted from HEK293FT cells using the Qiagen RNeasy Plus Mini 
kit. 500ng of RNA was reverse-transcribed into cDNA using qScript cDNA SuperMix 
20uL reaction kit (Quanta BioSciences). cDNA samples were diluted to 100µL using 
DEPC-treated water. Next, 5µL of diluted cDNA was amplified using primers (Table 
3.11) through the use of the LightCycler 480 SYBR Green I Master polymerase kit 
(Roche) and a LightCycler 480 Instrument II (Roche). Relative fold-changes were 
determined using the Ct method. 
3.5.7 Vector Proximity Computational Analysis 
Each desired 2-input 2-output Boolean function corresponded to a truth table with 
four rows and two output columns. The two output columns in each desired Boolean 
function f were mapped to an 8-dimensional binary vector t, which we call the Truth 
Table Vector. The fluorescent reporter signals measured from each of the two outputs, for 
each of the four input conditions from every genetic circuit implementation were also 
mapped to an 8-dimensional real vector s, which we call the Signal Vector. An Ideal 
Implementation of t is a circuit whose signal vector satisfies the equation ! = # ∙ %, for 
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some positive real number c. We quantified the correctness of a genetic circuit 
implementing Boolean function f by computing the angle  between the vectors t and s 
using the formula & = 	 cos+, -./0, where 1 = 	∑ %3 ∙ !̂3536, , 7 = 8∑ %39536, ∙ 8∑ !̂39536, , and 
ti and si are the i-th components of the vectors t and s. In computing , we capped the 
signal values si to a maximum of 2x104 a.u., denoted by !̂3 in the formulae above. The 
angular difference ranges from 0° (best) to 90° (worst). We quantified the strength of the 
signal vector by computing its Dynamic Range () of a genetic circuit implementation 
as : = min{3∶	@A6,}(!3) − max{3:@A6I}(!3). We computed the Dynamic Range separately for the two 
outputs of each circuit and omitted the computation for circuits where the magnitude 
differences were not defined. Consequently, we had to omit two circuits (always ON 
GFP/always OFF mCherry, and always ON GFP and mCherry) from the  computation 
and 16 GFP or mCherry outputs of circuits (but not both) from the  computation. 
3.5.8 Statistical Methods 
 All transient gene expression experiments involved transfection of DNA into n = 
3 separate cell cultures. Fluorescence intensities for each cell culture population was 
averaged and the standard error of the mean was taken. Stable integrations were 
performed once or in duplicate as indicated. 
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3.6 Figures 
 
Figure 3.1: Orthogonal site-specific tyrosine recombinases and serine integrases enable 
implementation of multi-input AND gates in mammalian cells. 
(a) Recombinases can perform simple BUF logic operations, either by tyrosine recombinase-mediated 
excision (left) or serine integrase-mediated inversion (right). (b) Recombinases are tested for their 
recombination efficiency and orthogonality on all BUF logic reporters. (c) A 6-input AND-gate that 
produces GFP when all inputs are present. M.F.I. = mean fluorescence intensity from n = 3 transfected 
cell cultures; a.u. = arbitrary units. Error bars represent standard error of the mean. 
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Figure 3.2: Orthogonal site-specific tyrosine recombinases and serine integrases enable 
implementation of multi-input AND gates in mammalian cells. 
(a) Recombinases are tested for their recombination efficiency and orthogonality on all BUF logic 
reporters. (b) A 6-input AND-gate that produces GFP when all inputs are present. % Cells ON 
calculated from n = 3 transfected cell cultures; a.u. = arbitrary units. Error bars represent standard 
error of the mean. 
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Figure 3.3: Recombinase cross-reactivity dose-response profile of Cre, Dre, VCre and Vika 
(a) Summary of intended and unintended recombination of Cre, Dre, VCre and Vika site-specific 
recombinases. Cre and Dre are mutually cross-reactive, whereas VCre can recombine Vika’s 
recombination sites, but not the other way around. (b) Dose-response profile of Cre (left) and Dre 
(right) on both Cre and Dre reporter constructs. (c) Dose-response profile of VCre (left) and Vika 
(right) on both VCre and Vika reporter constructs. Mean fluorescence intensity is plotted from n = 3 
transfected cell cultures; a.u. = arbitrary units. Error bars represent standard error of the mean. 
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Figure 3.4: Recombinase-based 2-input, 1-output Boolean logic gates using Cre and Flp 
recombinases 
Recombination sites for Cre and Flp are placed around termination sequences or GFP to enable or 
disable GFP expression. In this fashion all sixteen Boolean logic functions were created in mammalian 
cells. 
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Figure 3.5: Heterospecific recombination sites 
Heterospecific recombination sites for Cre, Flp, and VCre are placed around termination sequences 
before a GFP sequence. 
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Figure 3.6: 2-input BLADE platform can produce four distinct output functions based on two 
inputs 
(a) 2-input BLADE template on one plasmid with a single transcriptional unit. This template contains 
four distinct regions of DNA (addresses) downstream of a promoter. Each address corresponds to an 
output function and is accessed or deleted via site-specific DNA recombination. Each address can be 
programmed from different configurations ranging from zero-inputs to Boolean functions. The first 
address (Z00), which is the closest to the promoter, corresponds to a state where no recombinase is 
		
105 
expressed (A = 0, B = 0). If the Z00 address contains a protein coding sequence, then that gene will be 
expressed. Gene expression from the other addresses downstream of Z00 will be blocked by the 
presence of Z00 protein coding region. In the presence of recombinase A, which corresponds to state 
(A = 1, B = 0), addresses Z00 and Z01 will be removed, thus moving address Z10 directly downstream 
of the promoter and allowing gene expression of address Z10 only to occur. Similarly, when only 
recombinase B is present (A = 0, B = 1), addresses Z00 and Z10 are excised, allowing Z01 to be moved 
directly downstream of the promoter. Finally, when both recombinases are expressed (A = 1, B = 1), 
addresses Z00, Z01, Z10 are all excised, thus placing Z11 downstream of the promoter unobstructed by 
the other addresses. (b) Integrated 2-input BLADE decoder with tagBFP, EGFP, iRFP720, and 
mRuby2 as addresses Z00, Z10, Z01, and Z11 respectively. Plasmids constitutively expressing Cre and/or 
Flp are then stably integrated in. Three days of doxycycline (DOX) treatment is used to permit the 
rtTA-VP48 protein to bind to the tetracycline response elements promoter (pTRE) to activate gene 
expression. Mean fluorescence intensity (MFI) is plotted of either n = 1 or n = 2 independent 
integrations. a.u. = arbitrary units. 
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Figure 3.7: Unique Nucleotide Sequence guided assembly provides a fast and modular approach 
for creating DNA constructs 
Genes are first cloned into part entry vectors that contain 40bp unique nucleotide sequences (UNSes). 
These part vectors are then digested with either Asc1+Not1 or Asc1+Nhe1 restriction endonucleases 
to expose UNSes. The part fragments are then gel purified and assembled into a linearized destination 
vector using Gibson isothermal assembly. Details are described in [160]. 
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Figure 3.8: 2-input BLADE platform can produce four distinct output functions based on two 
inputs 
Integrated 2-input BLADE decoder with tagBFP, EGFP, iRFP720, and mRuby2 as addresses Z00, Z10, 
Z01, and Z11 respectively. Plasmids constitutively expressing Cre and/or Flp are then stably integrated 
in. Three days of doxycycline (DOX) treatment is used to permit the rtTA-VP48 protein to bind to the 
tetracycline response elements promoter (pTRE) to activate gene expression. % Cells ON is plotted of 
either n = 1 or n = 2 integrations. a.u. = arbitrary units. 
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Figure 3.9: Construction of two-input BLADE constructs using Unique Nucleotide Sequence 
Guided Assembly 
(a) To create a two-input BLADE construct, part vectors are created that contain output states for each 
address. The part vectors, along with a destination (DEST) vector, are digested and gel purified to 
expose unique nucleotide sequences (UNSes). (b) The part fragments and linearized destination vector 
are then assembled together in order of UNS via Gibson isothermal assembly to form the final 
expression vector. 
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Figure 3.10: Fluorescence histograms for 2-input decoder in non-induced Jurkat T lymphocytes 
2-input decoder produces a particular fluorescent protein for each row of the truth table. Grey 
histograms indicate wildtype Jurkat cells, unshaded colored histograms indicate OFF states and 
shaded colored histograms indicate ON states. Data are shown for one of the integrations. 
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Figure 3.11: Fluorescence histograms for 2-input decoder in doxycycline-induced Jurkat T 
lymphocytes 
2-input decoder produces a particular fluorescent protein for each row of the truth table. Grey 
histograms indicate wildtype Jurkat cells, unshaded colored histograms indicate OFF states and 
shaded colored histograms indicate ON states. Data is shown for one of the integrations. 
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Figure 3.12: Output response of integrated doxycycline-inducible decoder in Jurkat T cells can 
be easily modulated by dosage of doxycycline. 
2-input decoder produces a particular fluorescent protein for each row of the truth table. Unshaded 
colored dots indicate OFF states and shaded colored dots indicate ON states. Data is indicated for 
number of replicate integrations (n=1 or n=2) plotted. 
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Figure 3.13: Functionality of integrated doxycycline decoder in Jurkat T cells can be maintained 
over a couple weeks. 
2-input decoder produces a particular fluorescent protein for each row of the truth table. Unshaded 
colored circles indicate OFF states and shaded colored circles indicate ON states; cells here were 
maintained with doxycycline induction starting from day 0. Unshaded colored squares indicate OFF 
states and shaded colored squares indicate ON states; cells here were maintained with doxycycline 
induction starting from day 14 and were not induced with doxycycline prior to that point. Data is 
indicated for number of replicate integrations (n=1 or n=2) plotted. 
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Figure 3.14: Fluorescence bar charts and histograms for 2-input decoder in HEK293FT cells 
2-input decoder produces a particular fluorescent protein for each row of the truth table. (a) 2-input 
BLADE template with tagBFP, EGFP, iRFP720, and mRuby2 as addresses Z00, Z10, Z01, and Z11 
respectively. Mean fluorescence intensity from n = 3 independent transfections. a.u. = arbitrary units. 
Error bars represent standard error of the mean. (b) Grey histograms indicate wildtype HEK293FT, 
unshaded colored histograms indicate OFF states and shaded colored histograms indicate ON states. 
Data is shown for one of the three replicate transfected cell cultures. 
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Figure 3.15: One hundred and thirteen distinct gene circuits with up to two inputs and two 
outputs implemented using the 2-input BLADE template 
(a) To generate 2-input, 2-ouput circuits, a 2-input BLADE template can be configured with different 
combinations of output functions: zero-output (transcription termination sequence), one-output (GFP 
or mCherry) or two-output (GFP-T2A-mCherry). (b) A diverse library of >100 gene circuits, each 
shown as an individual column with predicted truth table GFP/mCherry ON/OFF behavior (black = no 
output, green = GFP ON, red = mCherry ON) and corresponding experimental averaged single-cell 
results obtained from flow cytometry.  (c) Angles between each Signal Vector and corresponding 
Intended Truth Table Vectors are plotted versus worst-case dynamic range values for GFP (dG) and 
mCherry (dM) signals. Shown above is an expanded view of one of the logic gates made using this 
platform. M.F.I. = mean fluorescence intensity from n = 3 transfected cell cultures; a.u. = arbitrary 
units. Error bars represent standard error of the mean. 
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Figure 3.16: One hundred and thirteen distinct gene circuits with up to two inputs and two 
outputs implemented using the 2-input BLADE template 
(a) To generate 2-input, 2-ouput circuits, a 2-input BLADE template can be configured with different 
combinations of output functions: zero-output (transcription termination sequence), one-output (GFP 
or mCherry) or two-output (GFP-T2A-mCherry). (b) A diverse library of >100 gene circuits, each 
shown as an individual column with predicted truth table GFP/mCherry ON/OFF behavior (black = no 
output, green = GFP ON, red = mCherry ON) and corresponding experimental averaged single-cell 
results obtained from flow cytometry.  (c) Angles between each Signal Vector and corresponding 
Intended Truth Table Vectors are plotted versus worst-case dynamic range values for GFP (dG) and 
mCherry (dM) signals. Shown above is an expanded view of one of the logic gates made using this 
platform. % Cells ON is calculated from n = 3 transfected cell cultures. Error bars represent standard 
error of the mean. 
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Figure 3.17: Determination of angular global rank amongst possible 255 truth tables for circuits 
made using the 2-input-2-output BLADE platform 
For a particular genetic circuit, angles between the Intended Truth Table vector and all 255 (up to 2-
input, up to 2-output, excluding the 0-input-0-output FALSE) truth tables vectors were found 
(Theoretical Angle), where an angle of zero indicates the intended truth table vector (squared in blue). 
Similarly, the angles between the signal vector and all possible truth table vectors were found 
(Measured Angle), where the lowest angle indicates the best truth table match. The global rank n is 
determined by how many (n) other truth tables were closer than the intended truth table. The first two 
plots (a) and (b) indicate two circuits (Gate 89 and Gate 71, respectively) that achieved a global rank 0 
and VP angle scores around 0° and 10°, respectively. The bottom plot (c) indicates Gate 94, where the 
signal vector was closer to one other truth table than the intended truth table (VP global rank 1); this 
circuit had a higher VP angle score as well around 20°. 
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Figure 3.18: Field-programmable storage and retrieval of logic and memory using a Boolean 
Logic Look-Up Table (LUT) 
The Boolean Logic LUT is a six-input-one-output genetic circuit that receives two data inputs, A and 
B, and is controlled by four select inputs, S1, S2, S3, and S4, producing an output of GFP. The select 
inputs are used to change data input-output behavior; each combination configures the circuit to any of 
the sixteen Boolean logic gates. F.I. = fluorescence intensity from n = 3 independent transfections. 
Error bars represent standard error of the mean. 
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Figure 3.19: Field-programmable storage and retrieval of logic and memory using a Boolean 
Logic Look-Up Table (LUT) 
The Boolean Logic LUT is a six-input-one-output genetic device that receives two data inputs, A and 
B, and is controlled by four select inputs, S1, S2, S3, and S4, producing an output of GFP. The select 
inputs are used to change data input-output behavior; each combination configures the device to any 
of the sixteen Boolean logic gates. F.I. = fluorescence intensity from n = 3 transfected cell cultures. 
Error bars represent standard error of the mean. 
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Figure 3.20: Alternative versions of the Boolean Logic Look-up Table (LUT) 
(a) A Boolean Logic LUT using Dre, Vika, B3 and VCre as select inputs. Red circles indicate areas 
where cross-reactivity made detectable changes in circuit response. (b) The same Boolean LUT using 
low amounts of select inputs to reduce cross-reactivity effects of Cre/Dre and VCre/Vika, as 
noticeably illustrated in the AND and A gates. Red circles indicate areas where cross-reactivity was 
resolved. 
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Figure 3.21: A 3-input BLADE template can be applied to create 3-input arithmetic 
computational circuits 
(a) The 3-input BLADE template can receive up to three inputs and produce eight distinct output 
functions. (b) Three 3-input-2-output binary arithmetic computational circuits made using the 3-input 
BLADE template. The full adder can add A + B + C while the full subtractor calculates A – B – C. 
For addition, input C, output P, and output Q represent Carry In, Carry Out and Sum, respectively. For 
subtraction, input C, output P, and output Q signify Borrow In, Borrow Out and Difference, 
respectively. The half adder-subtractor performs either binary addition of A + B or binary subtraction 
of A – B depending on the presence of select input C. F.I. = fluorescence intensity from n = 3 
transfected cell cultures; a.u. = arbitrary units. Error bars represent standard error of the mean. 
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Figure 3.22: The three-input BLADE template can be used to generate eight distinct output 
functions 
The three-input BLADE template uses Cre, Flp, and VCre to generate eight distinct configurations of 
DNA that each code for a distinct output function. 
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Figure 3.23: Construction of three-input BLADE constructs using Unique Nucleotide Sequence 
Guided Assembly 
(a) To create a three-input BLADE construct, part vectors are created that contain output states for 
each address. The part vectors, along with a destination (DEST) vector, are digested and gel purified 
to expose unique nucleotide sequences (UNSes). (b) The part fragments and linearized destination 
vector are then assembled together in order of UNS via Gibson isothermal assembly to form the final 
expression vector. 
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Figure 3.24: A 3-input BLADE template can be applied to create 3-input arithmetic 
computational circuits 
(a) The 3-input BLADE template can receive up to three inputs and produce eight distinct output 
functions. (b) Three 3-input-2-output binary arithmetic computational circuits made using the 3-input 
BLADE template. The full adder can add A + B + C while the full subtractor calculates A – B – C. 
For addition, input C, output P, and output Q represent Carry In, Carry Out and Sum, respectively. For 
subtraction, input C, output P, and output Q signify Borrow In, Borrow Out and Difference, 
respectively. The half adder-subtractor performs either binary addition of A + B or binary subtraction 
of A – B depending on the presence of select input C. % Cells ON is calculated from n = 3 transfected 
cell cultures. Error bars represent standard error of the mean. 
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Figure 3.25: Recursive construction of BLADE templates to form up to N-input, N-output 
combinatorial logic 
A BLADE template with and an alternate orthogonal version can be placed into a 1-input BLADE 
template to increase the input order by one. This approach can be repeated for generating N-input, M-
output logic with 2N addresses. 
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Figure 3.26: Interfacing BLADE with biologically relevant inputs and outputs 
(a) Small molecules, 4-hydroxytamoxifen (4OHT) and abscisic acid (ABA), are used to induce Cre 
and Flp recombination activities, respectively, on a decoder circuit containing four fluorescent protein 
outputs. Chemical induction of Cre recombination is achieved through 4OHT-mediated translocation 
of a Cre protein fused to mutated estrogen nuclear receptors (ERT2) from the cytoplasm to the nucleus. 
Chemical induction of Flp recombination is achieved through a split Flp recombinase construct fused 
to ABA-binding domains ABI and PYL. Mean fluorescence intensity is plotted from n = 3 transfected 
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cell cultures and error bars indicate the standard error of the mean. (b) Small molecules, 4OHT and 
ABA, are used to induce Cre and Flp recombination activities on a decoder circuit interfaced with a 
dCas9-VPR (VP64, p65, Rta) transcription activator. Four human genomic promoters are targets for 
activation via association of corresponding guide RNAs (gRNA) with dCas9-VPR. Total RNA was 
collected and averaged relative fold changes in target mRNA expression were obtained through 
quantitative real-time PCR of n = 3 transfected cell cultures. Error bars represent the standard error of 
the mean. 
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Figure 3.27: Interfacing BLADE with biologically relevant inputs and outputs displayed with 
cell percentages 
Small molecules, 4-hydroxytamoxifen (4OHT) and abscisic acid (ABA), are used to induce Cre and 
Flp recombination activities, respectively, on a decoder circuit containing four fluorescent protein 
outputs. Chemical induction of Cre recombination is achieved through 4OHT-mediated translocation 
of a Cre protein fused to mutated estrogen nuclear receptors (ERT2) from the cytoplasm to the nucleus. 
Chemical induction of Flp recombination is achieved through a split Flp recombinase construct fused 
to ABA-binding domains ABI and PYL. Calculated % Cells ON is plotted from n = 3 transfected cell 
cultures and error bars indicate the standard error of the mean. 
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Figure 3.28: Mean fluorescence intensity values for 2-Input 4-hydroxytamoxifen and abscisic 
acid-inducible decoder in HEK293FT cells over two days represented with histograms 
2-Input decoder produces a particular fluorescent protein for each row of the truth table. Error bars 
indicate standard error of the mean of three transfected cell cultures. 
		
132 
 
Figure 3.29: Mean fluorescence intensity values for 2-Input 4-hydroxytamoxifen and abscisic 
acid-inducible decoder in HEK293FT cells over two days represented as a line plot 
2-Input decoder produces a particular fluorescent protein for each row of the truth table. Error bars 
indicate standard error of the mean of three transfected cell cultures. 
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Figure 3.30: Fluorescence histograms for 2-Input 4-hydroxytamoxifen and abscisic acid-
inducible decoder in HEK293FT cells over two days 
2-Input decoder produces a particular fluorescent protein for each row of the truth table. Grey 
histograms indicate wildtype HEK293FT, unshaded colored histograms indicate OFF states and 
shaded colored histograms indicate ON states. Data is shown for one of the transfected cell cultures 
and for six time points in the z-axis. 
		
134 
Figure 3.31: 5’ recombination site additions do not diminish dCas9-VPR transcription 
activation 
Co-transfection of guide RNA expression plasmids that contain cloning scars (U1 UNS sequence) or 
FRT and lox2272 sites do not show diminished dCas9-VPR activation of a plasmid containing target 
sequences upstream a minimal promoter and an mCherry fluorescent protein sequence. Mean 
fluorescence intensity is from n = 3 transfected cell cultures; a.u. = arbitrary units. Error bars represent 
standard error of the mean. 
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Figure 3.32: Flow cytometric gating procedures for transient transfection of HEK293FT human 
embryonic kidney cells 
(a) Instruments are set initially with an FSC threshold of 500 arbitrary units, which filters out a small 
part of the debris population. All cells are then gated for viable HEK293FT cells as depicted in the 
pink gates above. Next, a transfection positive gate is made by gating for the top 0.1% transfection 
marker-expressing (LSS-mOrange or BFP) wild type HEK293FT cells. This gate is then applied to 
transfected cells and all analyses are done from cells within this gate. (b) An example of a 
compensation matrix generated through FlowJo’s auto-compensation tool using single positive 
fluorescent cells and universal negative wild type cells. 
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Figure 3.33: Comparison of uncompensated and compensated universal negative and GFP+ 
HEK293FT cells 
Wild type HEK293FT cells are used as a universal negative and cells transfected with pCAG-EGFP 
are used for GFP+ control. 
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Figure 3.34: Comparison of uncompensated and compensated BFP+ and mRuby2+ HEK293FT 
cells 
Cells transfected with pCAG-tagBFP are used for BFP+ control and cells transfected with pCAG-
mRuby2 are used for mRuby2+ control. 
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Figure 3.35: Comparison of uncompensated and compensated iRFP+ and LSSmOrange+ 
HEK293FT cells 
Cells transfected with pCAG-iRFP720 are used for iRFP+ control and cells transfected with pCAG-
LSSmOrange are used for LSSmOrange+ control. 
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3.6 Tables 
Table 3.1: Setup of buffer gates and recombinase expression plasmids for recombinase cross-reactivity table as detailed in Figure 3.1b, 
in addition to co-transfection with 62.5ng pCAG-tagBFP (pBW462) and 62.5ng pCAG-FALSE (pBW363). 
 Reporter à loxP FRT rox SloxM1 VloxP vox B3RT KDRT B2RT RSRT 
ϕC31 
attB/P 
bxb1 
attB/P None 
Enz Plasmid ID pBW338 pBW339 pBW364 pBW271 pBW273 pBW275 pBW276 pBW750 pBW278 pBW279 pBW409 
pBW40
6 
pBW36
3 
iCre pBW390 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
FlpO pBW391 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
DreO pBW431 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
SCre pBW432 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
VCre pBW433 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
Vika pBW434 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
B3 pBW435 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
KD pBW436 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
B2 pBW437 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
R pBW438 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
ϕC31 pBW440 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
bxb1 pBW439 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
None pBW363 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 62.5 ng ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
62.5 ng 
ea. 
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Table 3.2: Transient transfection setup for 2-input, 1-output logic gates detailed in Figure 3.4. 
 
 
 
Logic gate 
Gate Plasmid ID ng 
NOR pBW334 25 
OR pBW335 25 
AND pBW336 25 
NAND pBW337 25 
A pBW338 25 
B pBW339 25 
NOTA pBW340 25 
NOTB pBW341 25 
A IMPLY B pBW342 25 
B IMPLY A pBW343 25 
A NIMPLY B pBW344 25 
B NIMPLY A pBW345 25 
XOR pBW344 12.5 pBW345 12.5 
XNOR pBW334 12.5 pBW336 12.5 
TRUE pBW361 25 
FALSE pBW363 25 
XOR pBW448 25 
XNOR pBW450 25 
 
 
 
Reporter, 
ng 
Input 
State 
A B 
Enzyme 1, ng 
pCAG-iCre 
(pBW390) 
Enzyme 2, ng 
pCAG-FlpO 
(pBW391) 
Blank, ng 
pCAG-FALSE 
(pBW363) 
Marker, ng 
pCAG-tagBFP 
(pBW462) 
Values 
shown 
below 
0 0 0 0 50 25 
1 0 25 0 25 25 
0 1 0 25 25 25 
1 1 25 25 0 25 
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Table 3.3: Transient transfection setup of six-input AND gate as detailed in Figure 3.1c. 
AND 
GATE, 
ng 
pCAG-
6AND 
(pBW4
79) 
Enzyme 
1, ng 
pCAG-
PhiC31 
(pBW44
0) 
Enzyme 2, ng 
pCAG-bxb1 
(pBW439) 
Enzyme 3, ng 
pCAG-iCre 
(pBW390) 
Enzyme 4, ng 
pCAG-FlpO 
(pBW391) 
Enzyme 5, ng 
pCAG-B3 
(pBW435) 
Enzyme 6, ng 
pCAG-KD 
(pBW436) 
Blank, ng 
pCAG-
FALSE 
(pBW363) 
Marker, ng 
pCAG-tagBFP 
(pBW462) 
150 0 or 12.5 0 or 12.5 0 or 12.5 0 or 12.5 0 or 12.5 0 or 12.5 
Fill to total 
DNA amount 
= 250ng 
25 
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Table 3.4: Setup of buffer gates and recombinase expression plasmids for recombinase 
heterospecificity table as detailed in Figure 3.5. in addition to co-transfection with 62.5ng 
pCAG-tagBFP (pBW462), 62.5ng pCAG-FALSE (pBW363), and 62.5ng corresponding 
recombinase expression plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer Gate 
Buffer Gate pBW ng 
pCAG-loxP-STOP-loxP-GFP 338 25 
pCAG-lox2272-STOP-lox2272-GFP 427 25 
pCAG-loxN-STOP-loxN-GFP 428 25 
pCAG-loxP-STOP-lox2272-GFP 451 25 
pCAG-loxP-STOP-loxN-GFP 452 25 
pCAG-lox2272-STOP-loxN-GFP 453 25 
pCAG-FRT-STOP-FRT-GFP 339 25 
pCAG-F3-STOP-F3-GFP 429 25 
pCAG-F14-STOP-F14-GFP 430 25 
pCAG-FRT-STOP-F3-GFP 454 25 
pCAG-FRT-STOP-F14-GFP 455 25 
pCAG-F3-STOP-F14-GFP 456 25 
pCAG-VloxP-STOP-VloxP-GFP 273 25 
pCAG-Vlox2272-STOP-Vlox2272-GFP 274 25 
pCAG-VloxP-STOP-Vlox2272-GFP 331 25 
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 Table 3.5: Transient transfection setup for 2-input, 4-output decoder circuit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reporter 
pEXPRCAG-
DECODER 
(pBW842) 
Input State 
A B 
Enzyme 1, ng 
pCAG-iCre 
(pBW390) 
Enzyme 2, ng 
pCAG-FlpO 
(pBW391) 
Blank, ng 
pCAG-FALSE 
(pBW363) 
Marker, ng 
pCAG-LSS-
mOrange 
(pBW474) 
35.7 0 0 0 0 178.5 35.7 
1 0 35.7 0 142.8 35.7 
0 1 0 35.7 142.8 35.7 
1 1 35.7 35.7 107.1 35.7 
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 Table 3.6: Summary of Vector Proximity (VP) angle and global ranks scores for mean 
fluorescence intensity (MFI) data of the 2-input-2-output logic gate library in Figure 3.15 and % 
Cell ON data in Figure 3.16 in terms of number of circuits (#) and percentage of circuits (%). 
 
Analysis: MFI % CELLS ON 
VP Global Rank # % # % 
0 109 96.46% 112 99.12% 
1 4 3.54% 1 0.88% 
>1 0 0.00% 0 0.00% 
VP Angle # % # % 
<15° 106 93.81% 107 94.69% 
 
 
		
145 
Table 3.7: Transient transfection setup for six-input Boolean Logic Look-up Table genetic 
device in Figure 3.18.  
BOOLEAN 
LOGIC LUT, 
ng 
pEXPRCAG- 
LUT 
(pBW829) 
Input 
State 
A B 
Enzyme 1, 
ng 
pCAG-iCre 
(pBW390) 
Enzyme 2, 
ng 
pCAG-
FlpO 
(pBW391) 
Enzyme 3, 
ng 
pCAG-
PhiC31 
(pBW440) 
Enzyme 4, 
ng 
pCAG-Vika 
(pBW434) 
Enzyme 5, 
ng 
pCAG-B3 
 
(pBW435) 
Enzyme 6, 
ng 
pCAG-
bxb1 
(pBW439) 
Blank, ng 
pCAG-
FALSE 
(pBW363) 
Marker, ng 
pCAG-
tagBFP 
(pBW462) 
75 0 0 0 0 0 or 25 0 or 25 0 or 25 0 or 25 Fill to 
total DNA 
amount = 
250ng 
25 
1 0 25 0 
0 1 0 25 
1 1 25 25 
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Table 3.8: Transient transfection setup for 3-input logic gates detailed in Figure 3.21. 
Reporter 
Input 
State 
A B C 
Enzyme 1, ng 
pCAG-iCre 
(pBW390) 
Enzyme 2, ng 
pCAG-FlpO 
(pBW391) 
Enzyme 3, ng 
pCAG-VCre 
(pBW433) 
Blank, ng 
pCAG-
FALSE 
(pBW363) 
Marker, ng 
pCAG-tagBFP 
(pBW462) 
Values 
shown 
below 
0 0 0 0 0 0 0 62.5 
1 0 0 41.7 0 0 83.3 62.5 
0 1 0 0 41.7 0 83.3 62.5 
0 0 1 0 0 41.7 83.3 62.5 
1 1 0 41.7 41.7 0 41.7 62.5 
1 0 1 41.7 0 41.7 41.7 62.5 
0 1 1 0 41.7 41.7 41.7 62.5 
1 1 1 41.7 41.7 41.7 0 62.5 
 
Logic gate 
Gate Plasmid ID ng 
FULL ADDER pBW820 62.5 
FULL SUBTRACTOR pBW840 62.5 
HALF ADDER-SUBTRACTOR pBW841 62.5 
		
147 
Table 3.9: Transient transfection setup for inducible fluorescent protein decoder detailed in 
Figure 3.26a. 
 
Reporter 
pEXPRCAG-
DECODER 
(pBW842) 
4OHT 
(1µM) 
ABA 
(100µM) 
Recombinase 
Constructs 
Blank, ng 
pCAG-
FALSE 
(pBW363) 
Marker, ng 
pCAG-LSS-
mOrange 
(pBW474) 
35.7 0 0 35.7ng each: 
pDC56 (pCAG-ERT2-Cre-ERT2), 
pBW2286 (pCAG-Flp1-396-ABI), 
pBW2287 (pCAG-PYL-Flp397-423-
ABI) 
71.4 35.7 
1 0 
0 1 
1 1 
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Table 3.10: Transient transfection setup for CRISPR decoder detailed in Figure 3.26b. 
 
 
Reporter 
pEXPRCAG-
CRISPR-
DECODER 
(pBW842) 
4OHT 
(1µM) 
ABA 
(100µM) 
Recombinase 
Constructs 
CMV-
dCas9-VPR 
(Addgene: 
63798) 
Blank, ng 
pCAG-
FALSE 
(pBW363) 
Marker, ng 
pCAG-GFP 
(pBW361) 
35.7 0 0 35.7ng each: 
pDC16 (pSFFV-ERT2-Cre-
ERT2), 
pBW2286 (pCAG-Flp1-396-
ABI), 
pBW2287 (pCAG-PYL-
Flp397-423-ABI) 
35.7 35.7 35.7 
1 0 
0 1 
1 1 
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Table 3.11: Guide RNA target sequences and quantitative real-time PCR primers. Human guide 
RNAs and qPCR primers were adapted from [60]. 
NAME: SEQUENCE (5’ to 3’): 
gTRE ATCGTTCTCTATCACTGATA 
gNGN2 GGCGGTGGCGGGGGAGGAGG 
gMIAT GCGCCCATGAAATTTTAATG 
gACTC1 TGGCGCCCTGCCCTCTGCTG 
gTTN CCTTGGTGAAGTCTCCTTTG 
β-actin Forward CATGTACGTTGCTATCCAGGC 
β-actin Reverse CTCCTTAATGTCACGCACGAT 
NGN2 Forward TGGGTCTGGTACACGATTGC 
NGN2 Reverse GGGTCTCGATCTTGGTGAGC 
MIAT Forward TGGCTGGGGTTTGAACCTTT  
MIAT Reverse AGGAAGCTGTTCCAGACTGC 
ACTC1 Forward ATGTGTGACGACGAGGAGAC 
ACTC1 Reverse CACGATGGACGGGAAGAC 
TTN Forward TGTTGCCACTGGTGCTAAAG 
TTN Reverse ACAGCAGTCTTCTCCGCTTC 
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Table 3.12: Comparison between BLADE and recent recombinase-based circuit designs or the 
large-scale circuit design platform Cello. 
Key Attributes  BLADE   Siuti et al. [19]  
Bonnet et 
al. [18] 
Roquet et 
al. [122] 
Hsiao et 
al. [167] 
Nielsen et al. 
[152] 
Host Organism H. sapiens E. coli E. coli E. coli E. coli E. coli 
Operation Segment Excision 
Part 
Inversion 
Terminator 
Inversion 
Segment 
Excision/Inv
ersion 
Part 
Excision/In
version 
Promoter 
Repression 
Computing Resource Recombinase Transcription Factor 
Fundamental 
Building Block 
Line decoder 
circuit N/A 
NOR/NOT 
gates 
Device Design 
Algorithm 
Recursive 
algorithm 
based on # of 
inputsa 
Ad hoc for 
each 
circuitb 
Ad hoc for 
each circuit 
Exhaustive 
searchc 
Ad hoc for 
each circuit 
Heuristic 
searchd 
Number of 
functional and 
distinct circuits 
shown 
>110 ~20 ~10 ~5 1 ~60 
Metric (% success) Yes (>93%)e No Yes (75%) 
Maximum # of 
inputs shown 6 2 2 3 2 3 
Maximum # of 
transcriptional  
outputs from one 
circuit shown 
4 1 1 3-5f 2 1 
Types of outputs ORF, gRNA ORF ORF ORF ORF ORF 
 
a. Circuits with more inputs can be designed systematically with a recursive strategy that insert the 
BLADE circuit into another 1-input recombinase circuit. 
b. Each circuit has a unique design approach. 
c. All possible circuit permutations are based on available recombination sites are computationally 
evaluated. 
d. Circuit design is based on characterized parts and prior experimental results. 
e. 93.81% of circuits have a VP angle of ≤ 15°.  96.46% of circuits have a VP global rank equal to 0. 
f.  Some of the circuits can display up to 16 states, but only a subset of them can produce transcription 
outputs. 	
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